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By Daniel L. Myers
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in Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
(in Biological Sciences)
May, 2004
Chronic obstructive vascular disease is a major contributor to mortality in
developed nations. The pathology typically involves neointima formation accompanied
by vascular remodeling in the presence of inflammation. The disease can be modeled in
animals with the response to a direct injury of the vasculature. This text describes a
project examining the role of osteopontin (OPN) in vascular remodeling. The projectis
goal was to mechanistically describe the contribution of OPN to the vascular injury
response. The hypothesis that the presence of OPN affects the formation of neointima
and constrictive remodeling associated with vascular injury was addressed using the
strategy of comparing the remodeling response induced by carotid artery ligation of wild
type mice to mice with a null mutation in the geen encoding OPN at time points known to
be critical to lesion development.

OPN null mutant mice were compared to wild type mice before and after carotid
artery ligation. As substantial variation is observed in the response to carotid artery
ligation, the variance was analyzed for potential contributing variables. Distance from the
site of ligation was shown to be a significant predictor, and data was analyzed using
curvilinear regression. Prior to ligation, OPN null mice had increased heart rate, lower

blood pressure, and increased circulating lymphocytes compared to wild type mice. OPN
null vessels also demonstrated greater compliance accompanied by a loosely organized
collagen network. Following carotid artery ligation, significant differences were also found
in the remodeling response of OPN null animals. At 4 days after ligation, leukocyte
adhesiodinvasion was diminished by 10-fold in OPN null mice compared to wild type.
At 14 days following ligation, the ligated arteries of OPN null mice had smaller neointimal
lesions, but greater constrictive remodeling compared to wild type mice, resulting in
similar lumen area. Continued remodeling resulted in a similar morphological phenotype in
both groups at 28 days.
These data show that endogenous OPN regulates normal vascular physiology, and
contributes to the vascular remodeling response by regulating vascular compliance and the
inflammatory response.
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Chapter 1

THE INVESTIGATION OF CHRONIC OBSTRUCTIVE VASCULAR DISEASE

Cardiovascular disease is the leading cause of mortality in developed nations1 .
According to the World Health Organization, cardiovascular disease accounted for
16,585,000 deaths in the year 2002 or 29.3% of all deaths2. In the United States, the
American Heart Association reported cardiovascular disease accounts for 945,836 deaths
or 39.4% of all deaths for the year 2003. Though the contribution of cardiovascular
disease to mortality remains high, advances in the medical treatment of cardiovascular
disease have markedly improved outcomes. From 1990 to 2000, the death rate from
cardiovascular disease declined 17% in the United States. During this time, medical
management of cardiovascular disease improved with the introduction of cholesterol
lowering drugs, and vascular surgery methods improved with the introduction of stents.
With regard to vascular research, it was less than ten years ago that Thayer et al.
described the study of the molecular biology of vascular development as being in the
earliest staged. Since then, several of the key interactions involved with the development
of the vasculature have been identified. Today, as research continues to investigate the
basic functioning of the vasculature, we can expect discoveries that will lead to improved
therapies in the future.
Chronic obstructive vascular disease, the major contributor to cardiovascular
disease, is a group of distinct pathologies characterized by local changes in the vasculature
that result in the restriction of blood flow. The maladaptation causes decreased
oxygenation of downstream tissues, and, in some pathology, may result in embolism. As
is often the case, if the site of the disease is upstream of a vital area, then progression of
the disease may result in death due to failure of that vital area (e.g. stroke, myocardial
infarction, etc.). This text presents background information on the pathology common to

all chronic obstructive vascular disease and some recent research into the processes
underlying the disease.

Factors affect in^ cardiovascular function
It is necessary to consider the normal functions of vasculature before examining
specific aspects of chronic obstructive vascular pathology. In essence, the mammalian
circulatory system is an intermittent pump that circulates fluid through a hierarchical
closed system of pipes. Though conceptually simple, the mammalian circulatory system
is difficult to characterize due to the variables that affect each of its components5. Much
of the function of the cardiovascular system can be explained with Poiseuilleis law5:

Where Q is flow rate, Pi-P2 is the pressure difference, r is the radius of the tube, n is the
viscosity of the liquid, and L is the length of the tube.

Poiseuilleis law relates the movement of a fluid through a rigid pipe of known diameter to
the fluidis viscosity in response to a pressure drop. The law serves as a nice starting
point to examine cardiovascular function as it specifies variables involved in simple fluid
flow. However, Poiseuilleis law has two major shortcomings in its ability to describe
blood flow in the circulatory system. The law assumes constant pressure in a rigid tube,
whereas flow through the vasculature involves pulsatile pressures in an extensible tube.
The pulsatile changes in pressure and extensibility of the tube confound the mathematical

description of blood flow such that no expression has been proposed to describe the
system. Rather mathematical description is done by analogy to electrical systems (Ohms
law: Voltage = amperage x resistance) and series of pumps (windkessel). Thus,
experimental analysis of hemodynamics remains largely descriptive while efforts continue
to verifL the mathematical relations of the variables involved.

The blood
For the purposes of this study, the simplest component of the circulatory system
to consider is the blood. Viscosity, defined as shear stress (the force resisting blood flow)
divided by shear strain (the change in flow with distance measured perpendicular to the
flow), is the resistance of a fluid to change shape. According to Poiseuille, viscosity
affects the rate of blood flow. The effects of viscosity on the regional differences in flow
within the vessel have also been described6y7. In vitro, blood is normally 3-4 times as
viscous as water. A Newtonian fluid, like plasma, demonstrates constant viscosity at all
fluid flows. Blood, however, contains suspended cells that alter the fluidis behavior so as
to make it non-newtonian. Unlike plasma, blood demonstrates decreased viscosity at
increased flow rates. As red blood cells are, by far, the predominant suspended cell in
blood, changes in red blood cell shape or iron composition will substantially alter blood
viscosity8. As blood is a non-newtonian fluid, the parabolic flow pattern (i.e. faster in the
center and slower along the walls) demonstrated by Newtonian fluids is not observed.
This non-newtonian behavior of blood has physiologically beneficial effects. Blood is able
to offer little resistance to flow in vessels with high flow velocity such as large conduit
arteries, but is able to offer substantial resistance to flow in vessels with low flow
velocity such as small arterioles. Thls slow movement of blood cells facilitates gas
4

exchange and interaction with endothelial cells. Interestingly, an effect related to small
tube size occurs to prevent especially large viscosities from occurring at the very slow
flow velocities characteristic of capillaries9. Poiseuilleis law can also be used to consider
the effect of blood viscosity on the shear stress experienced by the vessel wall. At
constant shear strain, shear stress increases with increasing viscosity. Thus, the sliding
force exerted on the vessel wall increases with increasing viscosity of the fluid.

The heart
Whereas a consideration of the blood involves only its viscosity and nonnewtonian nature, a consideration of the heart involves pressure and cardiac output. For
the purposes of thls study, the heart can be viewed as a pump that at a regular rate injects
a specific amount of fluid at standard pressure into the vasculature. The pulsatile nature
of the heart results in the pressure within the arteries alternating between a high pressure
experienced during contraction of the left ventricle (systolic pressure), and a lower
pressure experienced during the Qstention of the left ventricle (diastolic pressure). The
pressure Qfference between the systolic pressure and the diastolic pressure is referred to
as the pulse pressure. It is the action of the heart that creates the pressure gradient
described in Poiseuilleis law. The left ventricle contracts with a force that is sufficient to
overcome the resting pressure of the vasculature and the viscosity of the blood. The work
done by this muscle contraction results in the movement of blood into the aorta and an
increase in aortic pressure. The amount of blood forced from the left ventricle into the
vasculature with each beat of the heart is called stroke volume. Stroke volume is
dependent on the difference in volume of the left ventricle when Qstended (diastole) and
when contracted (systole), though it is slightly less than this difference because of a small
5

reverse flow of blood back into the left ventricle before closure of the bicuspid valve.
Cardiac output is the amount of blood pumped by the heart in one minute, and is
dependent on both heart rate and stroke volume. (Cardiac output = heart rate x stroke
volume), but the linear relationship is only true at physiologic heart rates. Stroke volume
drops substantially with especially slow heart rateslo. Similar to Ohmis law, the mean
arterial pressure of the heart is determined solely by cardiac output and total vascular
resistance (Mean arterial pressure =cardiac output x total vascular resistance). Though it
has been suggested that pulse pressure may be a better indicator of cardiovascular
dlsease l , mean arterial pressure remains the focus of most blood pressure management
therapies.

The vasculature
Structure and function
The vasculature is a hierarchical system of distensible tubes. The levels of the
vasculature are defined by the initial branching of large arteries into smaller arteries, then
arterioles, then capillaries, then progressive merging into venules, then smaller and
ultimately to large veins. The composition of each blood vessel is critical to its function in
the hierarchy12. Blood vessels are composed of specifically arranged cell types in a
matrix that contains collagen, elastin, and proteoglycans. The dry weight of an artery is
approximately 30% of the total weight, with collagen and elastin typically being 50-75%
of the total dry weight13. Proteoglycans, consistent with their function as space fillers,
take up the majority of the extracellular space in arteries despite their low contribution to
total weight. The proteoglycans present in arteries include: versican, biglycan, and
6

decorin. The glycosaminoglycans hyaluronic acid, chondroitin sulfate, heparan sulfate,
and dermatan sulfate are also present14. The blood vessel wall has three distinct layers:
the adventitia, the media, and the intima (Figure 1A, C). The adventitia is the outermost
layer and is composed of loose connective tissue that is comprised mostly of collagens I
and 111~5.The media is the fleshy middle layer that, in a healthy blood vessel, constitutes
the bulk of the vessel wall. This layer appears as concentrically arranged layers of smooth
muscle cells in a matrix that consists mostly of collagen type I, 111, and ~ 1 separated
5
by
a fixed number of elastic lamina based on species and elastin expression16. The innermost
layer is the intima. As the endothelium is only a single cell layer thick, the intima of a
normal artery essentially does not contribute to the overall size of the artery, but does
provide a smooth, non-thrombogenic surface for blood flow. The tight junctions that join
the cells of a functional endothelium prevent plasma components from coming in contact
with the thrombogenic medial layer. Between the medial layer and intimal layer is a
basement membrane that contains collagen IV colocalizing with laminin, and collagen
v15717. Whereas collagen provides tensile strength, the elastin, which makes up the
elastic lamina of the medial layer, provides the extensible material that allows blood
vessels to demonstrate both circumferential and longitudinal stretch. As elastin fibers run
along the length of the vessel, longitudinal stretch has been shown to be influenced by
elastin content, circumferential stretch has been shown to be mediated by both elastin and
collagen content l 3, 8. An increase in collagen 1 content strengthens the vessel, but the
ratio of collagen I to collagen 111 can also affect the vascular flexibility17. Conversely, the
loss of type I collagen has been shown to substantially weaken arteries 19.
7

Figure 1. Neointimal lesion formation in the common carotid artery of rats
following endothelial denudation. Cross-section of the common carotid artery from a
rat following sham manipulation (A), and from a rat harvested two weeks after balloon
catheter denudation (B). The sections were stained with Massonis trichrome stain
indcating the presence of collagen in blue and proteoglycan in reddish purple. (C, D)
Parts of the vessel. Balloon catheter denudation induces an injury response that is
considered very similar to restenosis in humans. The elastic laminae appear as bands
withn the media.

The extensibility due to the elastin / collagen ratio13 of the vascular wall allows
the vessel to expand in response to an increase in pressure. T h s change in vessel size in
response to pressure, termed vascular compliance, is critical to proper vascular function.
The localized expansion of the aorta converts the kinetic energy of systole into a localized
potential energy. The energy is then released over diastole as a smooth, passive
constriction of the aorta that moves the blood forward, causing another localized
expansion. The active expansion 1 passive constriction of the artery dampens the pulsatile
flow of blood from the heart and is propagated along the vessel as a pressure wave. The
velocity with which the wave propagates along the artery, called pressure wave velocity,
is affected by both arterial compliance and blood viscosity. It should be noted that pulse
wave velocity does not equate to the velocity of blood through the vessels, and this point
allows distinction of the two functions of arteries: 1) to provide a conduit for blood flow,
2) to conduct the energy of the contraction of the heart necessary for movement of the
blood. The specialization of the arterial network can be appreciated with the realization
that different circuits of the circulatory system have different nutritive needs as well as
different energy requirements. The circulatory system meets these different needs through
the regulation of the lumen size and compliance of each individual artery. Whereas most
distensible materials demonstrate constant elasticity in response to varying force
(isotropy), blood vessels demonstrate different elasticities at different pressures
(anisotropy). This anisotropy is considered to be the most important feature of blood
vessels, as it provides the vessels with an efficient mechanism to regulate blood / energy
transfer20. The aorta perhaps best demonstrates the specialization for transport of blood
and energy. The aorta is tapered in size with the ascending aorta having the largest lumen
on cross section, and the base of the abdominal aorta having the smallest. Numerous
9

arteries branch from the aorta along its length to provide blood to different circuits. Not
only does the size of the aorta change along its length, but so does its compliance20. In
this way, the aorta is able to provide both the correct amount of blood to each circuit and
the correct amount of energy to properly move that blood through the given circuit.
Interestingly, a smaller, reverse pressure wave is initiated at each transition at branch
points. It is believed that these reverse pulse waves provide a feedback mechanism by
which energy (heart rate and strength of contraction) is finely regulated throughout the
circulatory system.
Vascular compliance also affects the amount of work the heart must do in order to
circulate the blood. Cardiac output has been related to arterial compliance as follows21.

Cardiac output = mean arterial pressure x (compliance 1 time constant)

As cardiac output increases linearly with an increase in compliance, increased compliance
reduces the pressure at which the heart must operate to maintain cardiac output. As mean
arterial pressure is related to total vascular resistance, the relationship suggests therapies
that increase compliance should result in decreased resistance to blood flow. However,
other factors, such as the alteration of total number of vessels must be considered when
selecting therapy, and the relationship should be considered valid only in time frames that
do not allow other compensations of the body. Vascular compliance has also been
documented to affect pulse pressure22-24. Such an effect is intuitive with the realization
that a rigid vasculature would not be able to dampen pressure.

The venous system has different specializations that reflect its function. Whereas
arteries need to be able to handle the high pressures that result from being proximal to the
heart, most of this energy is lost by the time the blood arrives in veins. Thus, the venous
system transports blood at relatively low pressure with its primary function being return
of the blood to the heart. Consistent with this lower pressure, veins demonstrate larger
lumen areas and smaller medial areas than arteries at a comparable level. As the large
driving pressure is largely absent, veins have specialized valves that keep the blood
moving in one direction.

Regulation of vascular hnction
Several hormones are known to regulate vascular tone including vasopressin,
endothelin, angiotensin, and nitric oxide. Vasopressin, also called anti-diuretic hormone, is
a vasoconstrictor that is used at the level of the entire circulatory system to regulate blood
pressure. Synthesized in the hypothalamus and secreted by the posterior hypothalamus,
vasopressin in small concentrations stimulates water resorption in the nephron, but in
larger concentration acts as a potent vasoconstrictor. Stimuli that lead to vasopressin
secretion include: low blood pressure, high blood osmomolarity, and activation of the
sympathetic nervous system.
The vascular response to the renin / angiotensin / aldosterone system is a method
by which pressure is regulated at both the system level and at the level of the individual
vessel. Renin is secreted in response to a drop in blood pressure or by a drop in plasma
sodium concentration. The juxtaglomerular cells of the kidney, located on the afferent
arterioles immediately adjacent to the entry to Bowmanis capsule of a nephron, sense the
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drop in blood pressure,. The juxtaglomerular cells are believed to respond as stretch
receptors to sense a change in blood volume. The juxtaglomerular cells are also positioned
next to cells of the distal convoluted tubule. As these cells of the distal convoluted tubule
are involved with the resorption of water 1 sensing of sodium, they are believed to
communicate with the juxtaglomerular cells. In response to sensing low sodium or low
blood pressure, the juxtaglomerular cells secrete renin into the blood. Renin acts as an
enzyme on angiotensinogen, a protein secreted by the liver that maintains a steady blood
concentration, to create angiotensin I. The conversion of angiotensinogen to angiotensin I
occurs in the general blood supply throughout the body. Angiotensin I has mild
vasoconstrictive properties that can provide a quick response to the low blood pressure
that led to its formation. Angiotensin I is acted upon by angiotensin converting enzyme to
form angiotensin 11. Though angiotensin converting enzyme is found in the general
circulation, its primary site of activity is in the lungs. It is estimated that in one pass
through the lungs, 80% of the angiotensin I is converted to angiotensin 11. Angiotensin I1
has two targets of action: 1) it acts on the general vasculature as a potent vasoconstrictor
and substantially raises blood pressure quickly, 2) it acts on the zona glomerulosa of the
adrenal gland to stimulate the secretion of aldosterone. Aldosterone acts on the nephron,
specifically the distal convoluted tubule, to increase resorption of sodium ions, which also
increases resorption of water. Aldosterone also has an action on the pituitary to increase
secretion of vasopressin. Thus, vasopressin would target the distal convoluted tubule to
increase sodium and water resorption as well. Angiotensin I1 stimulates collagen synthesis
in smooth muscle cells in vitro25. Thus, angiotensin I1 regulates vascular compliance both
in the short term, by smooth muscle tone, and long term, by altering the collagen / elastin
ratio. In response to certain stimuli, angiotensin converting enzyme can be expressed by

cells of the vascular wall allowing individual vessels some control of vascular tone.
Endothelin is also secreted by the endothelium where it acts as a potent vasoconstrictor
providing additional control of individual vessels26.
Another messenger molecule through which the endothelium regulates arterial
function is nitric oxide. As nitric oxide exists as a gas at standard temperature and
pressure, the detection of its presence is more difficult than for that of most other
signaling molecules. Typically, the presence of nitric oxide is determined by change in the
concentration of its precursors ( L-arginine and citnrlline). Nitric oxide in the vasculature
is the product of three different enzymes: endothelial nitric oxide synthase, inducible
nitric oxide synthase, and neural nitric oxide synthase27. As the rnRNAs resulting from
transcription of these genes are very similar, it is the promoter, and thus situations under
whch transcription occurs, that distinguishes the individuality of these genes. Endothelial
nitric oxide synthase is an endothelium specific gene that is always expressed to some
degree in endothelial cells.

Methods to measure vascular function
Laboratory methods exist to measure the movement of both blood and energy
through the vasculature. In the case of transport of blood, relevant measurements must be
made in vivo in a manner that does not interfere with blood flow. Doppler technology
allows blood flow measurements to be made from a vessel with minimal disturbance. As
sound waves are propagated through material interactions, blood flow through a vessel
can be determined by measuring the shift of sound waves as they pass through a blood
vessel.
13

Measurements of the movement of energy can be made with similar technology.
Ultrasound with sufficient sampling rates and resolution can be used to measure pulse
wave velocity. However, the determination of vascular compliance is not as straight
forward. Though arterial compliance can also be measured using ultrasound28 with
systolic / diastolic changes in vessel diameter used to calculate compliance in the
physiological pressure range, these methods rely on measurement of the change in vessel
diameter occurring with each beat of the heart. Critique of the method centers on the lack
of sufficient time for the vessel diameter to equilibrate at each pressure. Vascular
compliance measurements are often measured in vitro using direct methods. Methods
include the use of the wire rnyograph29,30 and the pressure myograph31732. Compliance
is determined in a wire myograph by longitudinally passing two thin but rigid wires
through the vessel lumen. A known force is then applied to the wires to separate them
from each other, resulting in the circumferential stretch of the vessel. Measurements can
then be made of the change in width of the vessel in response to the force to determine
extensibility of the vessel. Arteries studied in a wire myograph only demonstrate stretch
circumferentially as no change in the length of the vessel occurs. The pressure myograph
takes a different approach. The arterial segment is ligated at one end, then sutured to a
catheter at the other through which a known pressure can be applied. Like a balloon,
vessels studied in a pressure myograph stretch both circumferentially and longitudinally.
Comparison of compliance results of similar vessels in the different myographs reveals
that deformation of the vessel alters compliance biaxially33334, and results obtained from
one type of myograph may be very different from those obtained from the other. This

verifies that compliance measurements are geometry specific and has raised questions as
to the validity of measurements from these device&. Generally, the pressure myograph
is considered to be more physiologically relevant than wire myograph36.

Normal develo~mentof the vasculature
The vasculature forms earlv in develo~ment
The formation of the circulatory system begins following gastrulation, and
involves complex interactions of extravasated plasma proteins and endothelial cell
proteins induced by key cytokmes37. Blood and blood vessels begin as hemangioblasts
from the paraxial and splanchnopleural mesoderm forming concentrations in the gut, lung,
aorta, and yolk sac. With the correct signals, these blood / vascular stem cells differentiate
into endothelial cells and form primitive tubes. These blood islands then form the initial
blood and capillary networks of the body. The expression of three families of vascular
endothelium-specific growth factors are critical to the initiation of vasculogenesis: five
members of the vascular endothelial growth factor family, four members of the
angiopoietin family, and ephrin-B2. The interaction of these factors is complex, and the
reader is referred to Yancopoulos et a1.38 for review of the actions of these factors.
Additionally, Oettgen has reviewed the transcriptional regulation of blood vessel
development (Figure 2). Vascular endothelial growth factor, originally called vascular
permeability factor, appears to be the factor that initiates vessel formation, followed by
Angiopoeitin-1 and ephrin-B2, which are involved in vessel maturation39. The expression
of the ephrin-B4 receptor appears to be involved in the differentiation of arteries and
veins40.
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Figure 2. Growth factors and transcription factors involved in the development of
blood vessels. The development of blood vessels involves the complex interaction of

soluble messengers with differentially expressed receptors. (Figure taken from
0ettgen41.)

Vessel maturation involves both the recruitment of surrounding mesenchymal cells
then their differentiation into vascular smooth muscle cells, and the remodeling of the
extracellular matrix. The specific factors involved in maturation remains an area of
investigation, though the continued expression of angiopoeitin-1 appears to be involved in
the maintenance of vessel quiescence following vessel maturation38. The structural
remodeling of the vessel occurs in response to the chronic physical forces to which it is
exposed, such as pressure and shear stress, the specific function of the artery (transport
vs. gas exchange, large vs. small artery), and compensatory mechanisms at the level of the
individual artery and circulatory system. In vitro work suggests many factors may be
involved. Growth factors have been shown to have specific effects on vascular cells and
their supporting matrix. Consistent with the suggestion Schwartz and Liaw that fibroblast
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growth factor- 2 overcomes endogenous inhibition of proliferation of endothelial cells then
allows cells to enter mitosis in response to injury42, fibroblast growth factor expression
has been observed to increase cell number, but does not effect chondroitin sulfate content
or dermatan sulfate contentl4. Similarly, epidermal growth factor acts as a mitogen but
does not affect proteoglycan content. Opposing the action of these growth factors,
insulin-like growth factor iil and platelet derived growth factor do not act as an in vivo
mitogen for smooth muscle cells, but to stimulate synthesis of chondroitin sulfate,
dermatan sulfate and cell hypertrophy14. Interestingly, none of these growth factors
affected heperan sulfate depositionl4. Platelet derived growth factor, and transforming
growth factor - fJ also appear to play a role in vessel maturation41. The expression of
matrix metalloproteinases 2 and 9 occurs in the region around developing arteries, and null
mutation results in early embryonic lethality presumably due to disturbed vessel
formation43.
The development of blood cells has been reviewed44, with the specific lineage of
different white blood cells being a topic of debate. Blood cell differentiation and
development are also dependent on factors present in the area. Interestingly, the
development of blood cells from hemangioblasts involves expression of several proteins
that mark endothelial cell differentiation in response to many of the same factors. The
dfferentiation of blood components with blood vessels is believed to involve either
undiscovered differentiation factors, or local differences in concentration of lcnown
hfferentiation factors.

As compared to small arteries that form as small beds throughout the body during
development, large arteries develop with the patterning of the early embryo. As described
by ~ i l b e r t - 5following
,
gastrulation, thickened areas of intermediate mesoderm fold to
form lumens bilaterally. These cardiac primordia, though not containing blood,
demonstrate pulsations. The tubes are drawn closer together as neurulation proceeds, and
ultimately fuse to form the cardiac tube. In humans and mice, elongation of the central
portion of the tube results in formation of an S-shape with left A right orientation. This S
shaped structure develops into the 4 chambered heart. The anterior portion of the tube,
linking with the aorta vessel network, forms the aortic arches surrounding the pharynx,
while the posterior portion forms the vitelline veins. Meanwhile, the developing capillary
networks expand to join the large central vasculature. In humans and mice, some of the
aortic arches degenerate while others merge and expand to form the aorta, pulmonary
artery, and carotid arteries. The capillary network of the chorion merges with the vitelline
veins to supply nourished blood to the heart. Thus, the circulatory system forms fiom a
merger of several circulatory subsystems, as opposed to the expansion of a central
system.

Mature vessels remodel in res~onseto ~hvsicalforces
The metabolic needs of the body change throughout life as the body grows and
exercise levels fluctuate. In order to meet these needs, the cardiovascular system must
change as well. New blood vessels form in areas in areas of body growth, but instead of
being replaced, established large vessels remodel their structure so as to meet the bodyis
changing needs. Vascular response to acute needs is mediated by vascular tone in response
to vasoconstrictors and vasodilators. Hormones, such as angiotensin I1 and vasopressin,
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regulate the entire vasculature, while paracrine factors, such as nitric oxide and endothelin,
provide local control of individual vessels. Vascular function in response remodeling to
chronic needs is mediated by changes in vascular structure and smooth muscle cell
reactivity. It is likely that the structural changes occur in response to expression of genes
induced by certain vasoconstrictors~~~~6.
The normal remodeling of the vasculature that occurs throughout life has been best
demonstrated with the response of the vasculature to increased blood pressure. The
increase in blood pressure disturbs the cardiac output- total vascular resistance balance47,
and is detrimental to the body as it places greater structural demands on the vasculature
and shifts it out of the compliance range that is efficient for energy and blood transport.
The remodeling of individual blood vessels in response to increased pressure depends on
both the source of the pressure i n ~ r e a s eand
~ ~the
, ~position
~
of the vessel in the
vascular hierarchy50. Vascular remodeling may involve changes in gross vessel
morphology, changes in the structural composition of the vessel, and local changes in the
organization of the vasculature51-53. Changes in gross vessel morphology that have been
observed in the presence of increased blood pressure include: increased medial area
without changes in lumen area54, increased medial area with decreased lumen area55756,
and decreased lumen area without changes in medial area3l.57. Both increased56 and
decreased compliance3 ,58 have been observed in small vessels in response to increased
blood pressure. In large vessels, both decreased compliance59-63 and no change in
compliance50@ have been observed in response to increased pressure. The collagen

content of vessels has been observed to increase with age and may partially explain the
correlation of decreasing vascular compliance with increasing age65-67. In response to
increases in blood pressure, the vascular content of fibronectin68, and collagen V has
been observed to increase6 whereas elastin and proteoglycans69 decline. The
organization of the components also appears to be a source by which vessels can alter
function as studies have shown both no change in the physical properties of vessel wall
~ o m ~ o n e n t as
s ~well
~ ~as~physical
o
~ h a n ~ e s 6 9 7 ~ ~The
, 7 2 mechanism
.
by which
fibronectin participates in vascular remodeling was proposed to involve increased
attachment of smooth muscle cells to the matrix68. In response to increased blood
pressure, the vasculature has also been observed to reduce the number of small arteries
and capillaries in a local area (rarefaction)52753.
Changes in smooth muscle cell reactivity have also been observed to accompany
increased pressure73,74757. The increase in pressure that accompanies aging was
observed to correlate with decreased response to nitric oxide56767,75. The source of
hypertension appears to affect the response to specific vasoconstrictors / vasodilators is
different in different animal models of hypertension26,29729fi55.

Chronic obstructive vascular disease
Chronic obstructive vascular disease involves the remodeling of the vasculature in
the presence of inflammation. The degree of inflammation differs between the specific
dseases as well as the composition of the remodeled vascular areas. In general, a local

vascular lesion that includes both neointima formation and vascular remodeling (Figure
lB, D) characterizes the diseases. Whereas the intimal layer is normally thin and consists

of a single layer of endothelial cells, the neointima may become so thick as to fill the
lumen and consist of many layers of smooth muscle cell marker expressing cells. Whereas
tight junctions form between the endothelial cells of the normal intima, neointima
demonstrates substantial matrix deposition. The vascular remodeling that accompanies
chronic obstructive vascular disease may be positive (increase in vessel total cross
sectional area), or negative (decrease in vessel total cross sectional area) depending on the
specific dsease.

Examples of chronic obstructive vascular disease
Stenosis is perhaps the simplest of the chronic obstructive vascular pathologies
and occurs in response to a chronic drop in blood flow (reduction in shear stress). The
initial decrease in lumen area is due to vasoconstriction. Later, the reduction in lumen area
involves permanent changes in the vessel wall. The stimulus that initiates inflammation is
not known, but may be disruption of the tight junctions of endothelium from the longterm compression of the intimal layer allowing blood to contact the thrombogenic medial
layer. Neointima formation varies from minimal to severe.
Unlike stenosis, restenosis involves neointima formation that is often
accompanied by positive remodeling (an increase in the cross sectional area of the entire
ve~se1)~6.
In this case, the lesion forms in response to the surgical excision of stenosed
area or other disruption of the endotheliurn. Inflammation is induced by this direct injury
to the vasculature. Restenosis occurs in 30-50% of all angioplasties77

Atherosclerosis has a complex etiol0~~57~78,
and the reader is referred to Lusis
for review79. In essence, this disease is a response to injury caused by oxidative
modification of lipoprotein. Briefly, circulating lipoprotein is able to diffuse through the
tight junctions of the endothelium and accumulates along the basement membrane. Sites of
accumulation of lipoprotein are termed "fatty streaks" and are determined by
characteristics of blood flow. In a process similar to that whch will be described for all
chronic obstructive vascular disease, macrophages (but not neutrophils) migrate to the
subendothelial space to take up the lipoprotein. The lipoprotein along the basement
membrane undergoes modifications including oxidation, lipolysis, and proteolysis so as to
facilitate uptake by the macrophages. The modification of lipoprotein is believed to
involve the enzymes myeloperoxidase, sphingomyelinase, and secretory phospholipase in
the presence of several reactive oxygen species. The lipid-laden macrophages, now called
"foam cells", alter the developing neointima so as to make it less stable. Lesion rupture
generally occurs along lesion edges which are rich in foam cells and appears to involve an
altered balance of matrix deposition / degradation in response to inflammatory factors.
Interestingly, the incidence of myocardial infarction and stroke has been noted to increase
during acute infection suggesting the involvement mediators of immunity with vascular
disease.

Ex~erimentalmodels of chronic obstructive vascular disease
The remodeling of the vasculature that occurs in chronic obstructive vascular
disease is similar to the remodeling of the vasculature that occurs throughout life in that it
occurs in response to physical stimuli acting on the vessel. Whereas the vascular
remodeling which occurs throughout life represents a system level adaptation to a

changing body, the remodeling associated with chronic obstructive vascular disease is a
maladaptation to a local irritant. All of the chronic obstructive vascular diseases involve
vascular remodeling in the presence of inflammation and most of the damage that occurs in
lesion formation is due to the inflammatory response following the irritant. Though the
presentation of the vascular lesion, underlying cause, and degree of inflammation vary in
each chronic obstructive vascular disease, the vascular response to inflammation is
believed to be similar in each case. Thus, any method that reliably induces an
inflammatory response in the vasculature may be considered to be a model for the many
aspects common to all chronic obstructive vascular diseases. Current models include
animals whch have been genetically modified to remove a vasoprotective protein (e.g.
apolipoprotein E)~O,animals whch have been genetically modified to over-express
proteins which are harmful to vessels (e.g. renit@l, infusion of chemicals whch damage
vessels (e.g. lipopolysaccharide)82, and direct physical injury of the vessel. Direct injury
methods have included cauterizationg3, application of corrosive agent@,
electrocutiong5, endothelial denudationg6, dehydrationg7,c ~ f f i n ~ 8 8 ~vibrationgo,
89,
and

--Vascular Injury Events

Vasoconstn~tron
Neutrophrl lnvaslon
Platelet-Leukocyte Interactrons
Smooth Muscle Cell Prolrferatronfibrrn Deposltron
TGF-P Expressron
Macrophage lnvaslon
Advent~tralINOS Expression
Neorrit~maFormation

f

eNOS Depress~on
Tissue Factor Expressron
Matrix Metalloproteinase Expressron
Constrrctrve Remodelrnbg
Smooth Muscle Cell Apoptosis
Stable Neorntrma
Osteopontr n Expresslon

0

5

10

15

20

25

30

35

40

45

Days Following Injury

Figure 3. Timeline of events following vascular injury. Though there are many
different vascular injury models, many induced events are believed to be common to all
models. The precise timing of the events differs between models. INOS = inducible nitric
oxide synthase, eNOS = endothelial nitric oxide synthase, TGF-p = transforming growth
factor - p

Seauence of events lead in^ to chronic obstructive vascular disease
Animal models that involve direct injury of the vasculature allow more precise
temporal study of the injury response. Though specific timing of events varies between
models, a general pattern of platelet / leukocyte aggregation followed by smooth muscle
cell proliferation, migration, and extracellular matrix deposition can be identified. Studies
that have observed the injury response at different times have been especially helpful in
clarifying the processes of the injury response92-g4. Using information gathered from
studies using the many models, a general description of the vascular response to injury
can be made by dividing the injury response into three periods: early, middle, and late
(Figure 3).
The early period involves the first 4 days following injury. General responses to
the procedure as well as responses specific to the injured vasculature characterize the
immediate post-procedure period following induction of the inflammatory response. For
example, matrix metalloproteinase -9 expression is observed in the common carotid artery
of both ligated and sham manipulated mice immediately following surgery95. A second
example is that arteries typically respond to any manipulation with a vasoconstriction
whose duration seems determined by the level of trauma. Responses specific to the
injured vasculature can be seen beginning the day after the procedure. The strong
expression of adhesion molecules on the surface of endothelial cells is first observed soon
after injury93. Platelets in conjunction with leukocytes can be seen aggregating near the
endothelium92. The leukocytes involved in the initial interactions in the early period were
determined to be neutrophils, that are quickly joined by macrophagesg3. The leukocytes
extravasate and, in a reperfusion injury model, inhbition of neutrophil extravasation at

this time with annexin-1 has been shown to reduce neointima formation96. Proliferation
of medial smooth muscle cells coincides with this leukocyte invasion97, and smooth
muscle cell migration from the medial layer to the intimal layer is observed to begin 2 to 4
days after the procedure98. Deposition of collagen type ~11199,and fibrin deposition is
seen along the vessel wall92 also at this time, and, in models involving blood stasis, clot
formation may occur between 2-3 days post procedure92. Along with an increase in
transforming growth factor - $ expression, tissue factor is observed to be expressed
between the inner wall of the media and the forming fibrin layerloo. By the end of this
period, both neutrophils and macrophages are observed to have penetrated into the medial
layer93.
The period from 4 to 7 days following the procedure is marked by the appearance
of a platelet / fibrin rich neointima extending into the lumen92. Interleulun- 1 expression is
observed in the media at this time, then peaks at day 10101. In models that demonstrate
constrictive remodeling, the bulk of constrictive remodeling prior to day 7 is believed to
be due to vasoconstriction94.
From 7 to 28 days, cell replacement is evident in both the neointima and media as
both proliferation and apoptosis are observed. Smooth muscle cell proliferation is
described as optimal for observation until day 1492. Smooth muscle cell apoptosis occurs
after 7 days, and a decreased number of smooth muscle cells is observed at 14 days91394.
As this is the time that the observed constriction is increasingly unresponsive to
vasodilator, Rudic et al. speculated the structural changes were due to smooth muscle cell

apoptosisg4. Despite the loss in intimal cell number following day 14, intimal area has
generally been observed to increase due to continued matrix deposition. As current lesion
analyses do not consider the length of the involved arterial segment, the observed increase
in intimal area may reflect a lesion that extends over a larger segment and not an actual
increase in cross sectional area. At day 7, basal nitric oxide synthesis is observed to
decrease at this time without a concomitant change in endothelial nitric oxide synthase
level@. Additionally, inducible nitric oxide synthase expression is observed in the
adventitia from invading inflammatory cells102, and expression of matrix
metalloproteinase -2 is first observed to increase over its constitutive level at this time
and remains elevated throughout this period103. Interestingly, the expression of this
matrix metalloproteinase was shown to be related to flow restriction in the endothelial
denudation model, with no change in expression in the case of high flowl03. Angiotensin
converting enzyme expression is observed to increase along the lumen border between 1
to 2 weeks following injury104 and strong tissue factor expression persists in the
neointima. By day 14, cells expressing smooth muscle cell markers are present
throughout the neointimag2. Transfoming growth factor-b returns to baseline expression
at this time97 and interleukin-1 is no longer observed after this timelo]. By day 28 post
procedure, both neointimal formation and constrictive remodeling are believed to be stable
in that little change in these important parameters occurs91. The application of
vasodilator does not alter lumen area at this time, implying the vessel to be rigid.

Manv plavers mediate the vascular iniurv response
The vascular lesions of chronic obstructive vascular disease form in response to
the interactions of several cell types, secreted messengers, and modification of the
extracellular matrix. Though it is believed that neointima formation results from smooth
muscle proliferation in the media followed by migration to and further proliferation in the
intima, the migration of these cells has not been proven. Smooth muscle cells in the intima
display the smooth muscle cell markers of medial cells91, but they also display a
markedly different morphology. Whereas the nuclei of medial smooth muscle cells are
large and oval shaped on vessel cross section, the nuclei of the intimal smooth muscle cells
appear small and punctate in vessel cross section. Alternatively, it has been suggested
that the intimal smooth muscle cells are the result of differentiated adventitial fibroblasts
that migrated to the intimal05. Although intimal cells appear in the absence of
endotheliurn, it has also been suggested that the expression of smooth muscle cell markers
represents a loss of differentiation of endothelial cellsl05. This question as to the origin
of neointimal cells could be partially addressed with the use of mice containing an
inducible smooth muscle specific reporter construct in which the reporter is expressed
then inhibited just prior to injury. The appearance of reporter expressing cells in the
neointima would indicate migration from the media.

Cells
Endothelial cells appear to play a multi-faceted role in the response to injury.
Endothelial cell expression of cell adhesion molecules allows homing of inflammatory cells
to the site of injury. Cell adhesion molecules belonging to the integrin, selectin, and

immunoglobulin superfamily are expressed following injury, and loss of function of Mac1g77 067 07, selectins ( E , L , P ) I ~ ~intracellular
, ~ ~ ~ , adhesion molecule- 1]

]]

results in

decreased neointima formation. Platelet binding to sites of vascular injury is initiated with
the binding of platelet glycoprotein Ib-V-IX to von Willebrand factor on endothelial cells.
P-selectin and Mac-1 are involved in the interaction of platelets with white blood
cell~1~97112.
Despite the presence of the endothelium, the compressive force associated
with constrictive remodeling may directly interfere with the ability of the endothelium to
prevent the thrombogenic media from coming in contact with blood. The interaction of
platelets and leukocytes suggests the contact activation system may be involved in
mediating the vascular response to injury. Support for this possibility is provided by the
observation that overexpression of kallilcrein results in diminished macrophage
infiltration1

and neointirna formation1 l47l15. Endothelial cells are a critical source of

both vasoconstrictors (endothelin) and vasodilators in this system. Additionally,
endothelial cells express different growth factors in culture than in vivol16 suggesting the
disruption of the cells with injury may induce a different phenotype.
The inflammatory cells believed to participate in the injury response have not
been well characterized. Kumar and Lindner described the observation of macrophages in
both the intima and media using BMA BM8, a cell surface marker of macrophages,
immunostaining of cross sectionsgl. Since that time, neutrophils have been observed to be
the predominant inflammatory cell type in the first three days of response93. Little has
been done in addition to these studies to characterize the inflammatory cells mediating the
response to carotid artery ligation. Questions remaining to be answered involve the

identification of other leukocyte types in the injury response, and the determination of
the activation state of the invading leukocytes. The role of prostaglandin has been studied
in this model only through a drug studies in which aspirin was shown to have no effect on
the response to ligation27,102.

Vasodilators and vasoconstrictors
As with normal remodeling of the vasculature, vasodilators and growth factors
affect vascular remodeling in the presence of inflammation. The amount of vasodilator
present in the vessel during the early stages of the response to carotid artery ligation may
substantially reduce constrictive remodeling. The initial vasoconstriction in response to
injury may be due to reduced expression of endothelial nitric oxide synthase, as nitric
oxide expression is noted to be diminished and vessels changed to low flow do not
demonstrate altered response to angiotensin, aldosterone, prostanoids, or endothelin.
The loss of endothelial nitric oxide synthase function is believed to involve posttranslational modification as mRNA levels remain the same94. Interestingly, smooth
muscle cells become hypersensitive to nitric oxide at t h s time, and studies using nitric
oxide donors1 17 or calcium channel blockers, whch increase nitric oxide118, have shown
decreased neointima formation via a MEW extracellular signal related kinase
pathway119,120. However, arguing against this role for nitric oxide, endothelial
denudation results in an acute increase in diameter and compliance of rat arteries67. In
addition to this possibly important role as a vasodilator, nitric oxide has been shown to
inhibit smooth muscle cell proliferation 1migration, enhance endothelial cell migration and
reorganization94,121, and has anti-aggretory effects on platelets. Mice over-expressing
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endothelial nitric oxide synthase showed less neointima, no change in total area, had
decreased expression of endothelial adhesion molecules and subsequently fewer invading
inflammatory cells947102. The other source of nitric oxide in this system is from
inflammatory cells. Various leukocytes express inducible nitric oxide synthase, and upon
activation can secrete relatively large amounts of nitric oxide1O2. Besides being a potent
vasodilator, nitric oxide is a reactive oxygen species involved in the destruction of

Another important regulator of vascular tone that appears to have effects on the
injury response is angiotensin 11. Angiotensin I1 has been demonstrated to be involved in
atherosclerosis, hypertension and restenosis124. Though not secreted by the cells at the
site of injury, angiotensin concentration at the site of injury is elevated due to the
expression of angiotensin converting enzyme at the injury site along the lumen borderl25,
and inhibiting angiotensin converting enzyme limits neointima formation104 Angiotensin
infusion lead to iron deposition on renal tubules, heart and coronary arteries, but
neointima formation was blocked with an iron chelatorl26. In vitro Angiotensin I1 and
tumor necrosis factor - a induce smooth muscle cell proliferation via cyclooxygenase-2
activation of mitogen associated protein kinasel extracellular signal related k i n a ~ e land
~~,
inhibiting elastin synthesis in smooth muscle cells46.

Growth factors
The expression of several growth factors has been noted from endothelial cells,
smooth muscle cells, and inflammatory cells following injuryl28. fibroblast growth factor
-1 and fibroblast growth factor -2 have both been observed to alter the injury response.
Infusion of fibroblast growth factor -1 results in increased neointima formationl04, while
fibroblast growth factor -2 infusion following denudation lead to a 4 fold increase in
proliferation129. These effects may involve angiotensin as fibroblast growth factor has
been observed to induce angiotensin converting enzyme expression104. Blockade of
fibroblast growth factor -2 did not affect neointima size, but substantially reduced
constrictive remodeling130. As heparin is able to bind many growth factors including
fibroblast growth factor, it is not surprising then that heparin inhibits smooth muscle cell
proliferation and reduces neointima formation in a manner that was free of coagulation
effects113,131. Neither vascular endothelial growth factor nor one of its receptors FLK-1
was detected after injury, but high levels of another vascular endothelial growth factor
receptor, FLT-1, were seen after injuryl29. Consistent with the shear stress response
element GAGACC in its promoter, platelet derived growth factor is expressed following
injury in an injury model blood stasis. Epithelial growth factor expression has been
observed following injury from enothelial cells, smooth muscle cells, macrophages, and T
cells. The promoter of transforming growth factor - p also contains the shear stress
response element and expression of transforming growth factor - p following injury has
been observed to increase with increasing flow97. In vitro, transforming growth factor - fJ
i h b i t s vascular smooth muscle cell growth and migration and i h b i t s expression of
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proteins involved in matrix degradation (collagenase, elastase, urokinase)l 32, 33.
Following endothelial denudation, transforming growth factor - fJ and its type I1 receptor
expression localize to the wound edge, and blockade of transforming growth factor - fJ
type I1 receptor profoundly inhibits constrictive remodeling134. The effect is probably
due to transforming growth factor - fJ induction of collagen I and I11 expression. Other
hormones that appear to have an effect on the injury response are estrogen135, and 25
hydroxy cholesteroll36.

C~tokines
Regulators of immune function also have been demonstrated to affect the injury
response. In general, expression of proinflammatory factors leads to greater neointima
formation, and expression of anti-inflammatory factors leads to decreased neointima
formation. Tumor necrosis factor - a has been observed in atherosclerotic plaques and
following vascular injurylol. Tumor necrosis factor - a precedes smooth muscle cell
migration and leads to increased intracellular adhesion molecule-1 expression. Following
carotid artery ligation, mice modified to overexpress tumor necrosis factor - a
demonstrate increased neointima formation, whereas tumor necrosis factor - a null mice
demonstrate greatly reduced neointimalol. Similarly, interleulun - 1 is expressed
following vascular injury and interleukin - 1 receptor 1 null mice demonstrated 7 fold less
neointima than wild typelOl. Monocyte chemoattractant protein has been shown to be
chemotactic for macrophages, and blocking CCR2, the receptor for monocyte
chemoattractant protein-1, decreases neutrophil and macrophage invasion leading to less
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neointima formation115. Interestingly, infection of the vasculature with monocyte
chemoattractant protein-1 expressing virus does not lead to white blood cell accumulation
at the walls of the vasculature137 demonstrating the complex regulation of the vascular
injury response. Prostacyclin expression reduces neointima formation due to its ability to
inhibit smooth muscle cell proliferation and prevent platelet accumulationl38. Some
aspects of the injury response have been shown to be model specific as interleukin -10
expression has been shown to block atherosclerosis, but following injury interleukin - 10
null mice did not demonstrate the expected increase in neointima formation as compared
to wild type. Though dexarnethasone inhibits macrophage accumulation after injury 139,
primary cell lines derived from neointima showed decreased glucocorticoid receptor140
suggesting that the steroid has less effect on cells of the neointima.

The extracellular matrix
Vascular injury also results in substantial changes to the extracellular matrix. Tai
examined 68 genes involved in synthesis and breakdown of extra-cellular matrix using real
time polymerase chain reaction and found 47 were differentially expressed following
injury141. The matrix of the neointima is initiated with the deposition of fibrin along the
lumen border. It is possible that the majority of early neointima is simply clot attached
to the vessel wall. Consistent with this view, early neointima is observed to be eccentric,
vary substantially in area, and have large portions of the neointimal area occupied by
trapped red blood cells. Substantial remodeling in terms of both structure and
composition involving fibrinolysis84 results in later neointima appearing substantially

more dense and concentric. Fibrin has been shown to be a substrate for both endothelial
cell and smooth muscle cell migation92, and neointima formation was observed to be
substantially decreased in a carotid artery ligation study using fibrin deficient mice92.
Consistent with these results, inhibition of tissue factor by overexpression of tissue
factor pathway inhibitor resulted in decreased neointima formation.100. On the other
hand, overexpression of plasminogen did not alter neointima formation, but did alter the
response of the media89. The collagen fibers that form in the neointima are thcker than
those of the uninjured intima and have been shown to be thrombogenic15. Collagen type
IV, present in the basement membrane underlying the endothelial cells, but not in
uninjured intima, is present in neointimal5. In contrast, mature atherosclerotic plaques
contain mostly collagen I and collagen 111, moderate amounts of collagen V, but no
collagen ~ 1 4 2However,
.
collagen type IV may be found, along with collagens I, 111, V in
the fatty streaks that occur earlier in the development of plaques. Additionally, vascular
injury induces a decrease in elastinl43, resulting in vessel stiffening32.
Many components of the extracellular matrix that are expressed in response to
injury contain the sequence arginine-glycine-aspartic acid. Examples include fibronectin,
vitronectin, collagens, thrombospondin, fibrinogen, von Willebrandis factor, and
osteopontin ( 0 ~ ~ ) 1 4 The
4 . sequence is known to mediate interaction with integrin
receptors, and, in vitro, changes to the sequence around arginine - glycine - aspartic acid
affects binding to different r e ~ e ~ t o r s l 4 4 , 1Evidence
4~.
suggests that the aVp3 integrin is
especially important in interacting with these extracellular matrix components. Studies

have shown this integrin to be involved with tumor progressionl46, cell survivall47, cell
migration1487149, cell shape150, cell proliferation151, regulation of matrix
metalloproteinase expression152, angiogenesis153, vasodilationl54, and vascular
remodeling l

8. Intracellular signaling involved with aVP3 includes: phosphatidyl

inositol3 kinase, Phospholipase A, and calcium. The vasodilation of aortic rings in
response to arginine-glycine-asparticacid peptides requires aVf33 and is mediated by
phosphotidyl inositol 3 kinase 1 ~ k t l 5Interestingly,
~.
phosphotidyl inositol3 kinase is
known to physically associate with aVf33159. With regard to vascular disease, increased
aVf33 expression has been observed in lesions from patients with restenosis,
atherosclerosis, and transplant vascular disease 55,l60.
The expression of matrix metalloproteinase has been observed following injury lo3
and may be a mediator of the injury response. As these enzymes are known to remodel
extracellular matrix and breakdown basement membrane, they may be involved in the
remodeling of the neointima, and movement of cells from the media into the intima. The
differential expression of matrix metalloproteinase correlates with smooth muscle cell
migration152 and, though the size of the neointima remains the same, smooth muscle cell
migration is blocked with the matrix metalloproteinase inhibitor GM600116l. In addition
to these critical roles in the matrix modification, matrix metalloproteinases have also been
shown to modifL the functional activity of various matricellular proteins through cleavage
and subsequent exposure of cryptic sites within these molecules162. Thus, matrix
metalloproteinases may affect the injury response directly through enzymatic action on

matrix components, and indirectly, through the modification of signals to other responsemediating cells. Metalloproteinases identified so far include matrix metalloproteinase -2
and matrix metalloproteinase -9103 which our laboratory has also observed to cleave
OPN.

The work presented in this text
Goal
-

The work presented in this text was funded by the American Heart Association
(Grant #0250 150N) with the broad goal of advancing our understanding of the processes
that underlie chronic obstructive vascular disease such that interventions can be developed
to reduce the associated morbidity and mortality. The specific goal of the project was to
mechanistically describe the contribution of OPN to the vascular injury response. As will
be described in chapter 3, OPN expression is known to be regulated by factors expressed

in response to vascular injury, and high levels of OPN expression have been observed in
chronic obstructive vascular disease. OPN is an arginine-glycine-aspartic acid containing
protein that typically localizes to the matrix where it has been shown to alter the activity
of attached cells. With regard to inflammation, OPN may be either pro-inflammatory or
anti-inflammatory depending on the type and state of the tissue that produced it. Given,
as described in previous sections, that vascular injury recapitulates many of the factors
involved in chronic obstructive vascular disease, and the severity of the injury response
generally correlates with degree of inflammation, we reasoned that the expression of OPN
would have an effect on the vascular injury response. We further reasoned that
determination of mechanism of its action would provide key insights into the pathological
processes that underlie chronic obstructive vascular disease.
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We sought to test the following hypothesis: The presence of OPN affects the

formation of neointima and constrictive remodeling associated with vascular
injury. We suspected the loss of OPN would result in a diminished inflammatory
response leading to reduced neointima formation. To test the hypothesis we chose the
following strategy: Compare the injury response induced by carotid artery ligation

of wild type mice to mice with a null mutation of the gene encoding OPN at time
points known to be critical to lesion development. As described in previous sections,
the response to vascular injury involves the interaction of many different factors at
specific times. We believe that such complexity can only be accurately modeled in vivo,
and determination of mechanism of action requires observations at different stages of
lesion development to isolate the timing of OPN action. Additionally, as the vascular
response to injury is complex, we suspected large variation in injury response within
groups would require a large number of observations from subjects in a controlled
environment. These experimental needs preclude the use of human subjects. Mice are
commonly used as human models in the study of disease as, with respect to evolution,
they are closely related to humans, can be obtained in large numbers, and their
environment can be tightly controlled. The large vessels of mice are relevant for t h s
study, as they are similar in size to human small arterioles, a possible site of disease.
Mice have the added advantage of a ready availability of genetically modified lines.
Indeed, as OPN null mice are available, and, as this is an exploratory study, subjects more
closely related to humans are not required, we considered mice to be the ideal organism to
use in this study. As compared to other vascular injury models, carotid artery ligation has

been shown to be a relatively simple means of reliably inducing a consistent vascular
injury response in mice. The method has the additional benefit of being the most
commonly used method in mice facilitating the incorporation of this work with that of
others.

Overview
The work presented in this text makes a significant contribution not just to the
study of chronic obstructive vascular disease, but to the general study of vascular biology
as it identifies OPN as not only having a role in the response to vascular injury, but in the
function of normal, healthy arteries as well. Additionally, the work demonstrates the first
application of regression to the analysis of carotid artery ligation data that, due to
increased comparative power and quality of description, should facilitate future
experimentation and interpretation of studies.

Chapter 2

A REGRESSION MODEL OF THE RESPONSE TO MURINE

CAROTID ARTERY LIGATION

Chapter 2 Introduction
Chronic obstructive vascular pathology (e.g. stenosis, restenosis, arteriosclerosis)
remains a widespread health problem and the largest contributor to the morbidity and
mortality of both men and women in developed nations98. These illnesses each involve a
response to physical stimuli, such as oxidative injury or change in shear stress, and
inflammation resulting in vascular remodeling and neointima formation. As t h s pathology
has been shown to involve complex regulation of several cell types there continues to be
great need for in vivo models of vascular pathology. As described in chapter 1, there are
many different animal models of chronic obstructive vascular pathology including models
that involve physical manipulation as well as animals that, due to genetic background,
spontaneously demonstrate pathology. Each of these models has certain advantages and
disadvantages that must be considered when selecting a model of vascular injury. Though
the pathological processes may be similar, care must be taken in the interpretation of
experimental data that may or may not reflect aspects common to all models. For
example, OiBrien et al. observed the proliferation of smooth muscle cells in response to
endothelial denudation is different than that observed in atherosclerotic plaques163.
Additionally, as exemplified by Rogers et al., changes in experimental technique such as
route of drug delivery may profoundly affect the vascular injury response131.

Carotid artery lipation of mice
Murine models of vascular injury are especially useful in determining the
contribution of specific gene products to the vascular injury response as they take
advantage of the ready availability of genetically moddied mice. Comparison of the

vascular lesions of wild type mice to those of modified mice is one method that allows the
proteinis contribution to the injury response to be determined in a system free of
neutralizing antibodies. The complete ligation of the carotid artery is one method of
inducing an injury response in mice. Originally described by Kurnar and ~indnergl,this
model has the added advantage of being simple to perform. A small incision is made whch
allows exposure of the left common carotid artery. The artery is then ligated with suture
just proximal to its bifurcation into the internal and external carotid arteries (Figure 4).
Though the procedure does create a crushing injury, it is the loss of blood flow that is
believed to induce the vascular injury response. Since its original description, this model
has since been used to identify the role of plasma protein ~ ~ s t e m s181471
4 ~ 15,
cytokines101,164 and physical forces such as pressurel 18 and shear stress 91 in the
vascular remodeling response.
Several variations of the carotid artery ligation model have been used in specific
analyses. Song et al. performed ligation of the left common carotid artery in conjunction
with endothelial denudation of the right common carotid artery in order to observe the
effects of increased flow on the loss of endothelial cells97. Rudic et al. ligated the left
external carotid artery in order to observe the response of left common carotid artery to
reduced shear stress in the absence of injury94.

Internal Carotid

Figure 4. The site of the ligation in the carotid artery ligation model. The relative

ease with which the mouse genome can be manipulated provides a powerful tool with
which to study the role of various genes in the arterial response to vascular injury.
However, the blood vessels of mice are very small and as such preclude the use of balloon
catheter denudation to induce vascular injury. Carotid artery ligation is a means of
inducing a vascular injury in mice similar to the response induced by balloon catheter
denudation. In the carotid artery ligation procedure, the left common carotid is ligated just
proximal to the branchng of the internal and external carotid arteries. Because blood from
the left and right common carotid arteries combine at the Circle of Willis, either can be
completely occluded without causing significant harm to the animal.

Previous work has shown that the response to carotid artery ligation differs in
mice of different backgrounds implying the response to carotid artery ligation involves the
interaction of gene products from multiple loci 165. Interestingly, neointima formation and
constrictive remodeling were found to be separable responses. Some strains of mice
demonstrated large neointimas with little constrictive remodeling, and vice versal65.
Thus, the selection of genetic background in which to perform the study is critically
important as some strains show a marked response while others show little response. The
variable response of different strains suggests this model may have application in
quantiQing the contribution of different loci to the vascular injury response.

Problems in analvsis of the vascular resDonse to carotid arterv lipation
Whereas the vascular lesions in response to other direct injuries, such as
endothelial denudation, provide a relatively constant response over the involved arterial
segment, murine carotid artery ligation induces a response which is generally greatest at
the point of injury, then gradually diminishes over the involved arterial segment (3-5 rnrn
from the site of ligation). Additionally, the blockage of blood flow following complete
ligation of the carotid artery occasionally results in thrombus formation. If thrombus does
occur, it typically occurs in the 1 mm segment closest to the ligature. To avoid the
additional variable of thrombus formation, the 1 mm arterial segment closest to the
ligature is typically discarded. The change in response with distance from the site of
ligation and potential for thrombus complicate analysis of carotid artery ligation data.
Analyses of the lesions induced by carotid artery ligation have been done in one of two
ways: determination of mean response over the involved segment, or limiting analysis to a
specific portion of the segment. Both of these methods of analysis have problems that
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limit their interpretation. The representation of a predictably changing response with a
mean does not indicate important aspects of the data and results in excessively large
standard deviation. Limiting analyses to comparable regions begs the question as to how
comparable regions were determined as inspection of data prior to analysis violates
statistical premises. Both Yogo et al.27 and Sindermann et a1.166 recognized the need to
consider the effect of distance from the site of ligation in the analysis of response in this
model. In this study we attempt to build on their work with the presentation of a
regression analysis of data from a carotid artery ligation experiment. This method of
analysis provides non-graphical description of the injury response over distance that is
more precise than previous methods, as well as a way to compare the injury response
that provides statistical significance. The method demonstrates that distance from the site
of ligation is a significant predictor of the injury response. As regression analysis is a
commonly used statistical method, actual calculations are not presented, and the reader is
referred to SAS linear regression procedures 167 for description of the actual calculations
performed.

Cha~ter2 Methods
Murine carotid arterv lipation
The Institutional Animal Care and Use Committee approved all protocols. Mice
used in thls study were on a 129 x Black Swiss hybrid background and 16-24wk old males
were used for experiments. Ligation of the carotid arteries of mice was performed as
previously described91 on a test group of six mice and sham operations were performed
on a control group of six mice. Briefly, mice were anesthetized with a solution of

ketamine (80 mglkg, Fort Dodge Laboratories, Inc.) and xylazine (5mg/kg, Lloyd
Laboratories) injected intraperitoneally. The left common carotid artery was exposed
through a midline incision of the neck, and completely ligated just proximal to its
bifurcation into the internal and external carotid arteries. The incision was then closed
with surgical clips.
Two weeks following ligation, tissues were perfusion fixed with 4%
paraformaldehyde in 0.1 M / L sodium phosphate buffer, pH 7.3. Vessels were harvested
and embedded in paraffin such that initial sections from the block came from the internal /
external carotid arteries. At least 800 consecutive serial sections were cut from both
arteries of each mouse (7 pm thick). Sections including the ligature were easily identified
as they sectioned very poorly due to the clearly visible suture material.

Morphometric analvsis

As every section was saved and numbered, the distance from the site of ligation
(relative start site in the case of sham manipulation) and between sections was precisely
known. Sections of the internal / external carotid arteries were discarded. As analysis of
previous work using this strain showed that substantial change in remodeling could be
observed in sections 200 rnm apart, we considered sections 280 pm apart to be
independent observations. Ten sections from each mouse collected every 280 pm starting
at the site of the ligatiojn, thus representing an arterial segment approximately 3 rnm long,
were stained with orcein to accentuate the border between the layers of the vessel, and
morphometric analysis was performed. Digitized images of these vessels were analyzed
using image analysis soRware (NIH Image 1.60). The lumen surface, the perimeter of the
neointima, and the perimeter of the tunica media were traced, yielding circumference and

area of the lumen, internal elastic lamina, and external elastic lamina, respectively. The
medial area was calculated by subtracting the area defined by the internal elastic lamina
from the area defined by the external elastic lamina. Intimal area was calculated as the area
between the lumen surface and internal elastic lamina. As the shape of the cross sections
is often distorted due to sectioning and the neointima may be unevenly distributed, lumen
area could not be measured directly. Assuming the external elastic lamina was circular,
lumen area was calculated by subtracting medial area and intimal area from the total area
calculated from the circumference of the external elastic lamina (Table 1) .
Area
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I
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,
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1

-

= (external

-

-

I

elastic lamina circumference):! 1 (4p)

= Total Area - Medial

Area - Intimal Area

I

Table 1. Calculations to determine vessel areas

Data analysis
Data was analyzed using a standard PC with SAS v8.0 as described in results.

Cha~ter2 Results
Data collection
Mice (129xBlack Swiss) were separated into a test group (n=6) which underwent
carotid artery ligation, and a control group (n=6) which underwent sham manipulation.
We chose to harvest the carotid arteries at two weeks after the procedure as this is a

commonly used harvest time in carotid artery ligation experiments. Data were then
gathered as described in methods. Interpretation of the resulting data was initiated with
scatter plots of the different vessel areas versus distance for each mouse, and mean values
for each distance were calculated (Figure 5).

Figure 5. Example of scatter plot of morphometry measures. Measurements of lumen
area are indicated as a function of their corresponding distance from the site of ligation.
The data from both wild type and OPN null mice (discussed in chapter 3) appears wellbehaved (continuous and differentiable).

Consistent with the description of Kumar and Lindner, the response to ligation
was observed to be greatest near the ligature, then diminished with increasing distancegl.
As the scatter plots for both the individual mice and groups appeared well behaved
(continuous and differentiable at all points), we considered the data suitable for regression
analysis. The data was coded into SAS v8.0 including distance from the site of ligation for
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each analyzed section. The contribution of variability with distance to the total variability
was determined using Proc GLM as listed below. As changes in medial area, intimal area,
lumen area, and total area all contribute to the injury response, separate models were
calculated for each using the following command.

Proc GLM;
Model Total, Media, Intima, Lumen = ligature distance ligature*distance 1 solution;

The output listed both type I and type I11 sum of squares whch showed distance from
the ligature to be a significant predictor of lumen, intima, and medial area (Table 2). The
output also provided parameter estimates for the linear regression model. With the
exception of total area, these data indicated distance or the interaction of ligation with
distance to significantly contribute to total variance.

Repression model of the vascular resDonse to carotid artery liqation
We then sought to improve the models through fitting a curve to the mean
response. Various functions were tested against the data for best fit. The scatter plots
suggested y=arctan (x), y=e-x, and y=e- (x2) as possibilities for lumen and intimal area.
Models were determined for total, medial, intimal, and lumen area using Proc Reg (Table
3) with the following command.

Proc Reg;
Model total media intirna lumen = ligation distance ligdis;

Table 2. Much of the variation that occurs in the response to carotid artery ligation
can be attributed to distance from the site of ligation. Analysis of variance reveals

distance or interactions of distance with the presence of ligation to significantly predict
the vascular remodeling response. The data shows a consideration of distance
substantially increases the explained variance.

Source

Degrees
of
Freedom

Ligation
Distance
Ligation*Distance
Error
R-Square

1
1
1
85

Source

Degrees
of
Freedom

Ligation
Distance
Ligation*Distance
Error
R-Square

1
1
1
85

Source

Degrees
of
Freedom

Ligation
Distance
Ligation*Distance
Error
R-Square

1
1
1
85

Source

Degrees
of
Freedom

Ligation
Distance
Ligation*Distance
Error
R-Square

1
1

1
85

Total Area
Type I
Sum of
Squares
0.09604
0.00009
0.00869
0.34774
0.23 164

Pr>F

Type I11
Sum of
Squares

<0.0001
0.8769
0.1486

0.00585
0.00376
0.00869

Intimal Area
Type I
Pr>F
Sum of
Squares
0.22 187
0.02303
0.00642
0.1 1364
0.31244

0.0001
<O.OOO 1
0.03 11

Medial Area
Type I
Pr>F
Sum of
Squares
0.01994
0.00009
0.00103
0.01755
0.54534

<O.OOO 1
0.5176
0.0283

Lumen Area
Type I
Pr>F
Sum of
Squares
0.00039
0.02285
0.01997
0.16799
0.2046 1

0.6581
0.0010
0.002 1

Type I11
Sum of
Squares
0.02780
0.0062 1
0.00642

Type 111
Sum of
Squares
0.00198
0.00067
0.00103

Type I11
Sum of
Squares
0.01815
0.00 189
0.0 1997

With the exception of medial area, curvilinear regression models provided
substantial improvement over the linear models. For example, the curvilinear of intimal
area model had an r-square of 0.5548 using a x (117) curve as compared to 0.31244 for the
linear model. The linear model proved best for medial area.

Model: Area = B 1 + Bz(Ligation) + B3Pistance)

+ Bq(Ligated*Distance)

Table 3: Regression model of the response to carotid artery ligation. Curvilinear
regression can be used to describe the response to carotid artery ligation with greater
detail. All parameters demonstrated statistical significance.

Chapter 2 Discussion
As this study only examined the effects of ligation and distance from the ligation
on the vascular injury response, only wild type 129 x Black Swiss mice were used.
Within the model, the presence of ligation was described with a boolean variable (variable:

ligation), and the distance from the ligation was described with numeric variable (variable:
&stance). However, the analytical method can be easily extended to consider the effect of
individual genes by comparison of genetically modified mice to wild type. For example,
the comparison of wild type mice to mice lacking a particular gene can be performed with
the inclusion of an additional boolean variable (describes the presence of the gene. See
chapter 3 for analysis of the contribution of OPN to the remodeling response using this
method of analysis.). Similarly the comparison of wild type to mice that over-express a
particular gene product can be done with the inclusion of a numeric variable (describes the
amount of gene product present). The method is also easily extended to consider
interactions of test variables as demonstrated by the interaction of ligation with distance
(variable: ligation*distance) in this study.
Our analysis demonstrates that variation with distance is a significant contributor
to the total variance. Comparison of sum of squares shows distance contributes to 9%,
5%, 12%, and 66% of the explained variance for total, medial, intimal, and lumen area,
respectively. The models also provide a quantitative description of the change in vessel
areas with increasing data. Such information improves the description of the response as
compared to previously used methods. In this case, the analytical method also expands on
the description of two dimensional cross sectional areas by providing a consideration of
the third dimension (distance from the site of ligation). The models could serve as the
basis for the calculation of vessel layer volumes over an arterial segment.
As the vascular response is known to involve many factors, the flexibility of this
method to consider variable interactions makes these methods especially suitable. In this
study interaction is best demonstrated between the ligation procedure and distance in the
model of neointima formation. No significant change in intimal area occurs over an arterial

segment in the absence of ligation. However, there is significant change in intimal area over
an arterial segment in a ligated vessel. Phrased in terms of the intimal model, the
dependence of a distance effect on ligation is expressed as interaction of ligation and
distance being a significant predictor of intimal area. The clarification of the relationships
of the many variables involved in the vascular response provided by this analysis should
improve our understanding of obstructive vascular pathologies.

Clots alter the vascular resDonse
Further analysis of the data and regression models reveals that one mouse had a
response to ligation that was much greater than those of the other ligated mice.
Examination of the injury response in this mouse showed a large fibrous deposit in the
lumen in the region less than 1 mm from the ligature. This deposit is probably the result
of altered coagulation or a procedural problem and demonstrates the many influences
involved in the vascular response. Interestingly, the outlying data came not just from
sections containing the fibrous deposit, but also from sections observed to be free of the
deposit. We interpret this as showing that the presence of the deposit alters not just the
response of sections containing the clot, but the response along the entire vessel. Thus,
the routine exclusion of the data from the one-millimeter arterial segment closest to the
ligature removes the ability to detect an important source of response variation. To
determine the effect of this outlying data on the analysis we repeated the analysis with
the outlying data included. Though slight decreases in r-square values occurred for the
linear models of the different vessel areas, inclusion of the outlier data did not alter the
predictor significance of each variable. However, our attempt to improve the model with
curve fitting was not as successful. The curvilinear model offered little improvement over

the linear model using the data set containing outlying data. Thus, the exclusion of data
from mice that demonstrate an obviously atypical response to the ligation procedure is
important to the development of good models of the vascular response.

Theoretical problems
As often occurs in the regression analysis of data from experiments, there are
some theoretical problems in applying regression analysis to the data from carotid artery
ligation experiments. Regression analysis requires observations to be independent. This
condition is not met in these experiments as the response at one point in the artery is
physically linked to the response at every other point. We addressed this problem with
the selection of a distance between arterial points (280ym) over which previous work has
shown substantial change can occur. Regression analysis also requires equal variance at
each independent variable point. Examination of figure 6c shows that this condition is
clearly not met. We addressed t h ~ problem
s
with the use of weighted regression.
However, as the method did not improve the model, we chose not to present this
technique. We consider these theoretical problems to be minimal as compared to those of
typically used methods (appropriateness of mean to describe changing data and
inspection of data prior to analysis).

Figure 6. The vascular remodeling response varies with distance from the ligature.
Medial, intimal, lumen, and total areas are shown as a function of distance from a relative
start site for sham manipulated mice (A), and from the site of ligation for mice harvested

14 days following ligation of the carotid artery (B). Whle no significant change in the
vessel occurs with distance in the sham manipulated mice, substantial variation in vessel
areas occurs in ligated mice with increasing distance from the site of. If not accounted for,
this variation with distance can complicate description and comparison of the injury
response. (C) Standard deviations are shown for each mean intimal area calculated at
different distances from the site of ligation. Variation in intimal area not only occurs with
increasing distance from the site of ligation, but also occurs between mice of the same
background. Note that the variation in intimal area at each distance is not the same. Similar
results were obtained for medial, lumen, and total areas.
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Summarv
The vascular response induced by carotid artery ligation is typically localized to
the 3 to 5 mm region closest to the ligature. In this study the response was observed to
involve approximately 3 mm. Several other models of obstructive vascular pathology
involve a similar localized response. These pathology models might also benefit from
regression analysis as the responses are multifactoral and may vary with distance along an
arterial segment.
In summary, distance from the site of ligation was shown to be a significant
predictor of the vascular injury response in carotid artery ligation experiments. By
allowing simultaneous consideration of many factors, regression analysis provides both
improved description of the response as well as increased comparative power through
reduction of the unexplained variance.

Chapter 3
ALTERATIONS OF ARTERIAL PHYSIOLOGY IN OSTEOPONTIN NULL MICE

C h a ~ t e r3 Introduction
Both genetic and physiological factors have been shown to affect vascular

physiology/pathophysiology. ~lateletsg2,leukocytes 87,92,106,109,168, endothelial
cells169,170, and smooth muscle cells91,109,115,152 interact in a complex system
regulated by plasma protein systems84~114,115,~~tokines99,101,13~
,growth
factors130,134, and physical forces such as pressurel 13118 and shear stress 91~97,171to
remodel arteries in response to injury. In this study the arterial effects resulting from the
removal of OPN are examined.
OPN, also known as early after T cell activation-1 (ETA-I), 2ar, secreted
phosphoproteinl (SPPI), and bone sialoprotein 1 (BSP-I), was originally isolated as a
non-collagenous bone matrix protein172 which was later found to be identical to a protein
secreted by cancerous bone173. Early studies centered on a role for the protein in bone,
but it was soon realized that OPN was transiently expressed in many different tissues
undergoing remodeling following events such as infection, injury, or transformation.

The structure of SPP1. the pene that encodes osteopontin
The structures of the gene that codes for OPN, and the OPN protein itself have
been r e v i e ~ e d 1 ~ ~ ~ 1OPN
7 6 .is the product of the secreted phosphoprotein (sppl) gene
that exists as a single copy found on chromosome 5 near the ric genetic marker in mice,
and on chromosome 4 at q13 in humans. Sequences homologous to human OPN have been
found in rat, pig, cow, and chlcken. The mammalian sequences share approximately 40%
homology while the chicken sequence is only 19% homologous to human. The gene spans
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approximately 7 kb, contains 7 exons, and a 0.5 ii 2 kb promoter (Figure 7). Promoter
elements include sites related to ras activation (The APl site is for the binding of a
heterodimer of cFos / cJun), protein kinase C activation, a vitamin D response element, a
Pu box, a GAGACC element shown to be responsive to shear stress in platelet derived
growth factor%, and a CCAAT that binds a factor necessary for V-SRCstimulation of
OPN expression177. Consistent with the presence of these elements, OPN expression
has been shown to be induced by activated ras / MAPK178, calcium, and activated
~ ~ ~ 1Factors
7 9 known
.
to induce OPN expression include: parathyroid hormone,
Vitamin D3, angiotensin 11 80 (occurs via ERKlp38 pathway 8 I), and transfoming
,
estrogen, angiotensin converting enzyme inhibitors,
growth factor - ~ 1 8 2whereas

angiotensin I1 receptor antagonists have been shown to decrease OPN expression183.
Vitamin D induced OPN expression is suppressed by HES-1 in osteoblastsl84.
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Figure 7. The structure of the murine sppl gene. (Taken from Denhardt and

The structure of osteopontin protein
The OPN protein has an amino acid backbone that is 264 (chicken)lg5 to 3 17
(rat1173 amino acids in length dependng on the species (parenthetical references to
specific amino acids refer to the human protein). The protein is rich in aspartic acid,
glutamic acid and serine residues making it quite acidic. The secondary structure has been
predicted to contain 8 sections of alpha helix and 6 short beta sheet sequences175.
Circular dchroism experiments suggest a random tertiary structure in which regions
linking secondary structures are free to move1g6. Consistent with a flexible structure, no
crystal structure has been reported. The protein contains a relatively large number of
domains with potential biological activity (Figure 8). A transglutamination site is found
in the N terminal of the protein that can interact with the enzyme to crosslink OPN to
other proteins via glutamine ii lysine covalent bonds. Calcium binding loops are found in
the middle of both the N (aa 86-95) and C (aa 216-228) halves, and two heparin binding
loops are found the C terminal half of the protein (aa 168-174, aa 298-305). The integrin
binding arginine-glycine-asparbcacid sequence is found in the middle of the sequence (aa
158-162) close to an RS thrombin cleavage site187,188 (aa168-169). Interestingly, a
second integrin binding site containing the sequence sWYGLR lg9 (aa 162-168) is found
between the arginine-glycine-aspartic acid sequence and the thrombin cleavage site. This
second integrin binding site is cryptic for a s p 1 and a4bl as it only becomes active upon
cleavage of OPN by thrombinl90. Additionally a ELVTDFPTDLPAT site (aa 131-143)
upstream of the arginine - glycine - aspartic acid sequence can act as a second binding site
for a 4 p 1 172.
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Figure 8. The structure of osteopontin protein. (Modified from ~enhardtl97)

Modifications of osteopontin
Mechanisms that modifL the structure of osteopontin include differential
splicing, post-translational modification, cleavage, and cross-linking (Figure 9). Three
OPN splice variants have been described, all of which involve the selective splicing of
exon 3

l7192. Each of the OPN splice variants contains an export sequence, and upon

translation OPN enters the secretory pathway where it may be extensively modified. The
post translational modifications are both tissue and cell state specific193,194.
Modifications may include 0-linked glycosylation (6 sites), N-linked glycosylation (1
site), phosphorylation (15 sites) and sialation (10 sites)175, 1867195. The specific
phosphorylation of OPN can be done in a cell free system1757196 as ~ u t l e r l 8 6described
63

that the ser -X- glu (12 sites) sequence marks a potential site for casein kinase
phosphorylation of OPN, and the ser -X- glu sequence (2 sites) marks sites for
phosphorylation by casein kinase 11.
Specific post-translational modifications and interactions with other molecules
that modifL its conformation largely determine the biological activity of OPN. These
observations imply there is a strict structure ii function relationship in the action of OPN
and support the belief that the different forms of OPN have different biological activity.
Jono et al. demonstrated a phosphorylation requirement for OPN to mediate calcification
of smooth muscle ~ e l l s 1The
~ ~ binding
.
of OPN by factor H alters the OPN structure so
as to hide the arginine-glycine-aspartic acid sequence resulting in reduced
inflam~nationl~~.
Though OPN binding of calcium is not phosphorylation
the binding of calcium also alters OPN conformation200. The ability of OPN to bind
wells coated with collagen types I, IT, 111, IV, and V is calcium dependent186,201. OPN
has been shown to bind fibronectin 202. and osteocalcin and the binding of osteocalcin
inhibits transglutaminase action on 0 ~ ~ 2 0 3

A. Differential

Intracellular
Osteopontin

E. Cross-linked
Osteopontin

Figure 9. Osteopontin exists in many different forms. A) There are three known

OPN splice variants. B) Though intracellular OPN has been described, C) OPN generally
enters the secretory pathway where it may undergo extensive post-translational
modification. D) Upon leaving the cell, OPN may be cleaved by matrix metalloproteinases
or thrombin, or E) cross-linked by transglutaminase.

OPN is also structurally modified by cross-linking and cleavage of the protein.
OPN is a substrate for transglutaminase (factor 13a)195,204, which creates OPN
multimers and links OPN to fibronectin205. The formation of OPN multimers results in
increased collagen binding201. The cleavage of OPN by thrombin exposes the cryptic
integrin binding site and yields fragments with different biological activity than that of full
6 208. Other work in our laboratory has identified cleavage sites
length 0 ~ ~ 1 8 8 , 2 0207
for matrix metalloproteinases 3 and 7 in the OPN sequence2O9. Interestingly, one of these
sites is just four amino acids downstream of the arginine-glycine-asparticacid integrinbinding site (aa 166), and is internal to the cryptic integrin-binding site. The cleavage
effects of these matrix metalloproteinases on the cryptic integrin-binding site have not
been determined. Additionally, our laboratory has also observed OPN cleavage by matrix
metalloproteinase- 2 and matrix metalloproteinase - 9, but these cleavages have not yet
been characterized. The cleavage fragments do not equate to splice variants.
Though OPN is typically considered to be a secreted protein, Zohar et al. used
confocal microscopy to localize intracellular OPN outside of the secretory pathway210,
and has proposed this intracellular OPN to act as a survival factor21 1. Though intriguing,
the published experiments are not convincing as they lack important negative controls.

Receptors for osteopontin
There are eight known receptors for 0 ~ ~ 2 1 seven
2 , of which are integrins (Table
4). Binding affinities have only been determined for the aV containing integrins, all of
which occur in the nano-molar range174. As with most integrin mediated signaling,
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intracellular signaling as a result of OPN binding is complex. Rather than signaling through
the direct formation of a second messenger, integrins are believed to transduce signals
through the formation of an intracellular complex involving the cytoskeleton whose
specific three dimensional conformation results in enzymatic activity213. Key players in
integrin signaling include: focal adhesion kinase, integrin linked kinase, caveolin, paxillin,
and talin214. The ability of integrins to bind ligand is often believed to involve reversible
modification of the intracellular domains of the integrin subunits (activation). Thus,
integrins can exist in different states, and the ability of integrin to bind ligand is state
dependent. The binding of OPN to platelets and lymphocytes requires this activation of
the integrin215, 216. Pathways that have been shown to be activated in response to
integrin signaling include alterations in calcium levels including both increases and
decreases 75, alteration of pH, transient increase in protein phosphorylation, activation
of protein kinase C, mitogen associated protein kinase and phosphatidyl inositol3
lunase215. The biological effects resulting from interaction with OPN are mediated by
distinct integrins149. Particularly notable is the aVb3 integrin requirement for motility149
whereas other integrins are primarily involved with adhesionl49,217. The non-integrin
receptor for CD44 has been shown to exist as many different splice variants, only one
(exons v4,5,6,9) of which serves as an OPN receptor21*-220.~~44
binding of OPN is
involved in cell survival221 and is required for OPN mediated migration222-224.

OPN
Receptor

Features

am1

Adhesive receptor149

am3

Involved in angiogenesis297 and cell motility215,149

am5

Involved in cell motility148

a4p1

Involved in leukocyte adhesi0n2~8

a5p1

May be involved in the progression of atherosclerosis299

a8p1

May be involved in matrix deposition1 adhesion300

a9p1

Binds cryptic site exposed by thrombin cleavagelg8

pD44 1

Associated with tumor progression220

I

Table 4. Osteopontin Receptors

The biolo~icalrole of osteopontin
OPN expression has been observed in bone, kidney, tumors, placenta, the cochlea,
milk, and other bodily fluids225-227. The in vivo role of OPN has mostly been studied in
have been described. In
mice. Both OPN transgenic228,229 and knockout mi~e23092~1
both cases, the mice are viable, fertile, with a "normal" phenotype. The normal
appearance of these mice is not surprising given the transient nature of OPN expression in
response to tissue remodeling. Also, there is much redundancy in the domains of
matricellular proteins implying that the function of OPN, in most cases, can be fully
achieved by a combination of other matricellular proteins140. The findings of studies that
have observed alterations in response to the presence or absence of OPN are often
contradictory, probably owing to the functional effects of OPN conformation. These
contradictions and the diversity of the areas in which OPN is expressed make it difficult

to describe the function of OPN outside of the system being studied. Though the
fimctions of OPN in specific areas of the body can be described, a general description of
the role of OPN in the body remains conjectural232.

Bone
In bone, OPN has been shown to both facilitate and oppose bone resorption.
OPN has been shown to facilitate accumulation of osteoclasts at sites of bone
resorption233 and OPN null mice show altered osteoclast forrnation231. The expression
of OPN is required for bone resorption in response to parathyroid hormone234 and
decreased mechanical stress235 ,and OPN null mice are resistant to ovariectomy induced
bone resorption236. Additionally, osteolytic tumor cells that are osteolytic upregulate
OPN secretion in osteoblasts237. However, the effect of OPN on mineralization appears
to be conformation dependent as treatment of OPN with phosphatase increases
mineralization175.
The induction of OPN in response to stress has been observed in bone cells. In
vitro, OPN is induced with mechanical stimulation of osteoblast cells, and OPN null bone
cells are defective in producing nitric oxide in response to pulsatile fluid fl0w238,2~~.

As the kidney is a vital organ involved in the maintenance of blood pressure and
blood composition, the primary effects of OPN expression in this organ may cause
secondary effects throughout the body. OPN is expressed in the developing tubule
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epithelium240 and is constitutively present in the loop of Henle and the distal
convoluted tubule of adults1833240. OPN is differentially expressed by podocytes of the
glomerulus in response to stretch241, thus, as hypertension correlates with
a t h e r o s ~ l e r o s i s ~ ~it~is, ~
not
~ 3surprising
,
that increased OPN expression has been
observed in the kidneys of atherosclerotic patients244. Consistent with these pressure
effects on OPN expression, infusion of angiotensin 11 leads to increased OPN expression
throughout the kidney245.
OPN is also expressed throughout the kidney in tubulo-interstitial disease where
its effects are harmful as OPN null mice demonstrate less injury246 in response to
induced disease. Conversely, OPN null mice showed reduced tolerance to ischemia in
kidneys247. As described in chapter 1, the glomerular cells, juxtaglomerular cells, and cells
of the distal convoluted are believed to communicate such that pressure sensed at the
glomerulus can alter fluid resorption at the tubule. Expression of OPN in the distal tubule
suggests a role the maintenance of blood pressure and possible mediation of flow through
the glomerulus by inhibition of nitric oxide248.

Inflammation
The expression of OPN has been shown to have both proinflammatory and antiinflammatory effects1837249. In vitro, OPN has been shown to be expressed by and
chemotactic for macrophages250-252, and T ~ e l l s ~Indeed,
~ 3 . OPN may be the most
abundantly secreted protein from ~ - 1 ~ m ~ h o c Dendritic
~ t e s ~ cells
~ ~ and
. Langerhan cells
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also demonstrate migration toward OPN via a CD44laV mechanism255. Consistent with
OPN mediation of inflammatory cell migration, OPN null mice demonstrate a decreased
number of macrophages in tubulo-interstitial disease256, decreased ability to clear
respiratory infections257, and altered granuloma formation in response to sterile
irritantl04. Additionally, OPN has been shown to alter the interleukin -10 to interleukin 12 ratio258 so as to promote inflammation, and T cells from OPN null animals have
been shown to make less interleukin -10 and interferon gamma259. OPN expression
induces B cell proliferation and expression of immunoglobulin254. However, OPN also
demonstrates anti-inflammatory actions as it inhibits the synthesis of nitric oxide, a
reactive oxygen species, from inducible nitric oxide ~~nthase122,260,26~.

Cancer
The role of OPN in tumor progression has been studied also with seemingly
contradictory results probably owing to the results of modifications or cleavage on
protein function162,206,262. OPN expression has been observed in various
and OPN expression has been shown to increase in response to transformation264,265
leading to the use of OPN as a cancer marker2663267. OPN can be detected in the blood
when expressed in high amounts, and high plasma levels of OPN have been shown to
positively correlate with the metastatic potential of tumors268. Anti-sense blockade of
OPN leads to decreased malignancy269 and tum0ri~enicity2~0~27~.
However, the tumor
inhibiting functions of OPN have also been demonstrated as OPN null mice show
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accelerated tumor growth 1 progression262. OPN blocks 12-0 tetradecanoyl phorbol 13
acetate induced anchorage independence and reduces tumorigenicity and metastasis262.
Additionally, as described above, OPN has proinflammatory properties that should limit
tumor progression.
Similar to this role in promoting metastasis, OPN is believed to play a role in
embryonic implantation. OPN is expressed in decidua basalis where it aids the avoidance
of immune detection of fetal cells272. As in cancer, the conformation of OPN is
important as different charge forms affect acti0n2~3.

vasculature
OPN is present in small amounts in uninjured arteries274, but is abundantly
expressed by smooth muscle cells, endothelial cells1417274, and activated inflammatory
cells249,252,254 in injured arteries. Abundant OPN expression has also been observed in
human atherosclerotic lesions217 and thoracic aneurysms275 aortic valvular lesi0ns2~6,
left ventricular hypemophy277, and the presence of OPN in the blood following
angioplasty was shown to positively correlate with detrimental post procedural events77.
In vivo studies confirm the relevance of OPN during vascular remodeling and repair. Chiba
et al. observed that hematopoetic over-expression of OPN resulted in increased
atherosclerotic lesion formation229. The role of OPN as a physiological inhibitor of
vascular calcification was demonstrated in studies showing that spontaneous vascular

calcification in the matrix of Gla protein null mice was significantly increased on an OPN
null background278. Recently, the constitutive overexpression of OPN in mice was
observed to result in increased neointima formation following cuffing of the femoral
artery279. This overexpression of OPN in uninjured mice did not result in accumulation
of leukocytes in the vessel wall, indicating that control of vascular inflammation is
complex.
Though matrix metalloproteinase -295,103 and matrix metalloproteinase -9103 are
both expressed after vascular injury, and our laboratory has observed these matrix
metalloproteinases to cleave OPN, western blot shows the small amount of osteopontin
present in uninjured vessels exists as three widely separated bands, whereas following
injury only the heaviest band

Similar work
The in vivo work that most closely relates to the present study demonstrated
anti-OPN antibody to inhibit neointima formation following endothelial denudation280.
In this model, a catheter is inserted into an artery. The catheter is then inflated and pulled
back such that the endothelial lining of the blood vessel is stripped away. In this model,
OPN expression was initially observed two days following the procedure at the site of
injury. Strong OPN staining was observed in the newly formed neointima at day 7 peaked
at day 10, then slowly faded until absent by day 42.
This present study utilized a genetic OPN null murine model to test the
hypothesis that OPN regulates vascular remodeling in vivo. Our studies show the first
demonstration that endogenous OPN contributes to normal blood vessel structure and
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hnction, and that OPN is a regulator of both constrictive remodeling and neointimal
lesion formation. We provide evidence to support a model where OPN is mediating these
effects through regulation of vascular compliance and the inflammatory response.

Chapter 3 Methods
Animals
The Institutional Animal Care and Use Committee approved all animal protocols.
The OPN null mutant allele has been described281, and mice used in this study were 1624 week old males on a 129 x Black Swiss hybrid background. Heterozygous breeding
pairs were used to generate wild type or OPN null groups.

Blood count. hemodynamics. and vascular compliance
25ml of blood was obtained by retro-orbital collection (wild type: n=10, OPN
null: n=10), diluted to 200m1, and then analyzed by flow cytometry (Cell-Dyn 4000).
Blood pressure measurements were made using a Visitech BP200 tail cuff (wild type:
n=29, OPN null: n=17). Following a one-week conditioning period, 30 measurements
were made in a single daily session, over 5 days. The initial 10 measurements were
discarded, and the last 20 averaged to give a single daily blood pressure measurement for
each mouse.
Blood flow was measured using a Transonic flow probe with T160 computer interface
(wild type: n=18, OPN null: n=17). Animals were anesthetized with Avertin (2ml of
2.5% solution/100g, intraperitoneal), and the common carotid artery exposed and placed
within the Transonic flow probe (0.5 VB). Flow rate and heart rate were recorded
simultaneously.

Circumferential vascular compliance was measured using a standard
micromanipulator and microinjector (Nashige, IM 300). The left carotid artery was
isolated, sutured closed at the distal end, and sealed proximally with suture onto a
microneedle. The carotid artery was then inflated to 50, 100, 150,200, and 250 mm Hg.
Vessel diameter was measured from digitized images taken at each pressure (wild type:
n=4, OPN null: n=4). Extensibility was calculated as described by Li et al. 16 Example:
extensibility at 125 mmHg = [(diameter at 150 mmHg)-(diameter at 100 mmHg) /
(diameter at 100 mmHg)] x 100. A similar experiment was performed on a segment of the
descending aorta between the renal arteries and the iliac bifurcation (wild type: n=4, OPN
null: n=4). The isolated, segment was sutured closed at the proximal end, and sealed
distally with suture onto a blunted 30 gauge needle. The aorta was then uniformly
pressurized at a rate of 3mVmin using an Intraflow valve, with pressure measured with a
standard arterial line pressure transducer. Longitudinal compliance of carotid arteries was
determined similarly. The proximal end of the carotid artery was sutured closed, then tied
to the inside of a petri dish filled with lactated Ringeris solution. The distal end was then
sutured closed and tied so as to support a hanging weight. Vessel length was measured
from digital photographs taken before and after application of the force.

Arterial lipation model

Ligation of the left carotid arteries of mice (wild type: n=14 at 28d, n=8 at 14d,
n=8 at 4d, n=8 unmanipulated, n=6 sham; OPN null: n=14 at 28d, n=12 at 14d, n=8 at
4d, n=8 unmanipulated, n=6 sham) proximal to the internaVexterna1 carotid artery
bifurcation was performed as previously described91, with sham-operated mice used as
controls. Bromodeoxyuridine injections (100pl of 25 mglml bromodeoxyuridine solution)
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were given to each animal 15h and 1h prior to harvest. At the indicated times following
ligation, tissues were perfusion fixed with 4% paraformaldehyde in 0.1 M sodium
phosphate buffer, pH 7.3. The perfusate was allowed to drain from an incision in the left
carotid artery just proximal to the ligature. Vessels were harvested and embedded in
parafin. At least 800 consecutive serial sections were cut from both arteries of each
mouse (7 pm thick). For the right carotid artery, all analyzed sections were cut from the
vessel distal to the brachiocephalic artery.

Western blot analysis
Single ligated left carotid arteries were harvested and homogenized in lysis buffer
(50mM TRIS pH=8.0, 0.1% SDS, 2.5mM NaCL). 100 mg total proteidsample was
analyzed by SDS-PAGE (12.5% gel) followed by transfer to PVDF membrane, and
immunoblotted using an anti-OPN antibody282 (2k1, kindly provided by Dr. T. Uede).
Recombinant OPN was used as a positive control, and the relative amount of
OPNIsample was quantified using Imagequant software and normalization to smooth
muscle a-actin (clone 1A4, Sigma) levels. Triplicate analyses were performed.

Morphometric analvsis
Morphometric analysis was carried out on ligated left common carotid arteries
from both wild type and OPN null mice harvested at 14 and 28 days following ligation as
well as unmanipulated and sham manipulated controls. The contralateral right common
carotid artery was analyzed from harvests 28 days following ligation as well as
unmanipulated and sham manipulated. Eight sections were collected in 280 mm intervals
from the proximal 2.25mm closest to the ligature and orcein-stained for analysis (NTH

Image 1.60). The lumen surface, the perimeter of the neointima, and the perimeter of the
tunica media were traced, yielding circumference and area of the lumen, internal elastic
lamina, and external elastic lamina, respectively. Very small folds were not included in the
E L and external elastic lamina measurements. The medial area was calculated by
subtracting the area defined by the internal elastic lamina from the area defined by the
external elastic lamina. Intimal area was calculated as the area between the lumen surface
and internal elastic lamina. As the shape of the cross sections is often distorted due to
sectioning and the neointima may be unevenly distributed, lumen area could not be
measured directly. Assuming the external elastic lamina was circular, lumen area was
calculated by subtracting medial area and intimal area fiom the total area calculated fiom
the circumference of the external elastic lamina. No dfference in vessel areas was observed
between sham and unmanipulated animals. Sections adjacent to the orcein-stained sections
were stained with hematoxylin, and the number of nuclei in the media and intima for
ligated, contralateral, and control arteries were counted using software developed
specifically for thls project by Sentient Machines (Wells, ME), which was validated to be
consistent with manual counts. Lumen area of aortae of anesthetized unmanipulated mice
was also measured in situ by magnetic resonance angiography (Siemens Magneton)
utilizing blood flow for contrast (wild type: n=2, OPN null: n=2), and total artery size
quantified by direct measurement following surgical exposure of the carotid artery (wild
type: n=2, OPN null: n=2).

Immunostaining

A total of 8 sections, taken every 280 pm apart from each mouse harvested at 2
weeks following ligation were analyzed for cell proliferation using an antibromodeoxyuridine antibody (ICN Biomedicals) at a 1:2000 dilution followed by a
biotinylated secondary antibody at a 1:500 dilution. Similarly, a total of 10 sections,
taken every 280 pm apart from each mouse harvested at 4 days following ligation were
analyzed for leukocyte infiltration using a biotinylated anti-CD45 antibody (ICN
Biomedicals) at a 1:200 diluition. Sections were then treated with ABC reagent (Vector
Labs.), followed by incubation with 3,3i-diaminobenzidine (Sigma). Digitized images of
CD45 stained vessels were analyzed (NIH Image 1.60), and the staining quantified by
first thresholding all non-stained areas from the image, then measuring the remaining
positively stained area. Sections directly adjacent to those analyzed for leukocyte
infiltration were analyzed for apoptosis using a TUNEL assay kit (Clontech, Apo-alert
DNA fragmentation assay). Collagen was visualized with Massonis trichrome stain.

Statistical analysis

Morphometric data was structured as a two factor (OPN status, harvest time)
randomized design then analyzed using Fisheris LSD procedure. Two factor ANOVA
was performed on medial, intimal, lumen and total area measurements. Each showed OPN
to have a significant effect. The effect of OPN was then further clarified using Studentis ttest. Remaining comparisons involving a single variable (OPN genotype) at a single time
point were carried out with Studentis t-test. For the blood flow studies, measurements
were considered outliers if they were greater than 3 standard deviations away from the

mean, and were excluded from analysis of blood flow rate. Most of the outliers were
found to have heart rates lower than 250 beatslmin, which is consistent with the
observations of Hart et al. that heart rates below a certain point dramatically affect stroke
volume 10. Thus, we considered flow measurements in mice with heart rates lower than
250 beatslmin to be invalid, as flow rate correspondingly was decreased. All data are
reported as mean + standard deviation.

Chapter 3 Results
Vascular characteristics of OPN null mice
OPN null mice are overtly similar to wild type mice with respect to size, viability,
and physical activity. Low levels of OPN expression in unmanipulated arteries have been
previously described274. As the significance of this expression had not been explored, we
first compared OPN null mice to wild type mice with respect to cardiovascular function.
Blood pressure and heart rate measurements were obtained using the tail cuff method.
Unexpectedly, we observed significantly lower blood pressure and increased heart rate in
OPN null mice. Heart rate in the wild type group was 490 * 57 beatslmin, compared to
600 + 62 beatslmin in the OPN null group (p< 0.001)(Figure 1OA). Conversely, the
systolic blood pressure in wild type mice was 146 + 12.2 mm Hg, compared to 130 + 9.8

rnrn Hg in the OPN null mutants (p< O.OOl)(Figure 10B). As increased heart rate often
results from anemia, we analyzed blood cell composition by complete blood count (Table
5). No difference in red blood cells and platelets were observed, but a clear trend in
increased white blood cells was observed in the OPN null mice. Further analysis showed
that this WBC trend was accounted for by a significant increase in lymphocytes in OPN
null mice ( ~ 0 . 0 3 3 ) .

We then sought to determine the consequences of altered heart rate and blood
pressure on blood flow. A standard dosage of anesthesia resulted in equal heart rates in

*

both OPN null (3 14 40 beatslmin) and wild type mice (320 h 40 beatslmin). Blood flow
through the common carotid artery was determined by placing a flow probe around the
exposed vessel. The blood flow in wild type mice was significantly greater than in OPN
null mice at similar heart rates. Whereas the flow rate in the wild type vessels was 0.68 h

*

0.16 ml/min, average flow in the OPN null vessels was 0.50 0.21 mVmin
(@.029)(Figure 10 C). These results suggest that the increased heart rate in OPN null
animals may be due to a compensatory mechanism to counter reduced stroke volume.
Blood flow is predicted to be similar in conscious mice due to the higher heart rate in
OPN null mice.
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Figure 10. The loss of osteopontin results in altered hemodynamics. Though OPN
null mice are similar to wild type mice with respect to appearance, activity tolerance,
viability, and fertility, closer examination reveals a cardiovascular phenotype associated
with the loss of OPN. As compared to wild type, OPN null mice demonstrate: (A)
increased heart rate, (B) lower systolic blood pressure, and (C) decreased blood flow at
equivalent heart rates.

RBC

1

HGB

HCT

PLT

1

WBC

wild type

/ 11.3I+/- 0.62 . l8.36+/- 0.83 53.98+1- 2.92 l096+/- 120 '4.22+/--1.06-

OPN null

/11.10 +I-1.22 l6.64+/- 2.72 '53.28+/- 6.30 1273+1- 608 15.13+1- 0.09

p value

1

'

1

0.678

0.15

0.79

0.477

LYM

MONO

EOS

1

0.089

I

NEU

BAS0
0 +I
0-

0.77 +I
0.22
- 3.30+/- 0.95 '0.07+/- 0.06 0.08+/- 0.13

wild type

I

I

0.66 +I
0.20
- '4.37+/- 0.89 :0.08+1- 0.07 0.01+1- 0.02

OPN null

I

p value

0.305
I

1

0.033

,

00 +I
t

0.614

0.154

'

I

ND

Table 5. The loss of osteopontin results in an altered concentration of circulating
lymphocytes.
Comparison of complete blood count and differential cell counts of unrnanipulated
animals shows OPN null mice to have significantly more lymphocytes than wild type
mice. No significant difference in other values was noted. Values presented are average
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S.D. The p value listed represents a comparison in each population between the wild
type and OPN null values. RBC: red blood cells, HGB: hemoglobin, HCT: hematocrit,
PLT: platelets, WBC: white blood cells, NEU: neutrophils, LYM: lymphocytes, MONO:
monocytes, EOS: eosinophils, BASO: basophlls, ND: not defined. Italics indicate
statistical significance.

To determine if the vessel structure of OPN null mice reflected the altered
hemodynamics, we compared magnetic resonance angiograms of OPN null mice to wild
type. No difference was observed in aortic lumen areas (Figure 11). To expand on the
angiograms, digital photographs of surgically exposed common carotid arteries were
compared and also showed no difference in total vessel size. Having found no difference
in arterial morphology, we suspected that characteristics of the arterial wall were related
to the rate of blood flow and heart rate, and thus measured carotid artery wall
circumferential compliance as a function of intravascular pressure. Determination of small
vessel circumferential compliance has been previously described31. Left carotid arteries
were isolated, then inflated to specific pressures. Vessels were digitally recorded at
pressures from 50 mm Hg to 250 mm Hg. In OPN null mice, we observed a very rapid
increase in vessel wall diameter at physiological pressures (as determined by our blood
pressure measurements of these mice), while carotid arteries from wild type mice
demonstrated similar increases in size only at significantly higher pressures (Figure 12).
The percentage increases in vessel size at all pressures measured was greater in vessels
from OPN null mice, compared to wild type mice, and the responses of each carotid
artery sample of a particular genotype was remarkably consistent. To exclude the
possibility that increased circumferential compliance in OPN null mice was unique to the
carotid artery, a similar experiment was performed on segments of abdominal aorta
(Figures 13,14). The aorta demonstrated a similar increase in circumferential compliance in
OPN null animals as compared to wild type. Interestingly, the compliance data predicts
OPN null arteries to be larger than wild type at physiological pressures, which is not
observed in situ. We interpret this apparent inconsistency as supportive evidence of
increased vascular tone in OPN null mice as a compensatory mechanism for increased
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compliance. Circumferential compliance is mediated by both elastin and collagen content,
whereas longitudinal compliance is mediated predominantly by elastin13318. To
determine if longitudinal compliance was altered from that of wild type in OPN null mice,
a left common carotid artery from each group was mounted in a petri dish so as to
support different weights along the longitudinal axis. No difference in longitudinal
compliance was observed (Figure 15).
As the compliance data suggested collagen might be altered in OPN null mice, we
examined vessels histologically in an effort to determine the orign of the difference in
compliance. Arterial cross sections were stained with orcein and Massonis trichrome stain
to visualize elastin (Figure 16A,B) and collagen (Figure 16C,D), respectively. No
difference in the elastic fibers was noted between groups, but the collagenous matrix
appeared to be organized much more loosely in the OPN null mice, particularly in the
adventitial region. Interestingly, this observation does not correlate with the observation
of Giachelli et al. which localized the major sites of OPN expression to along the elastic
larninae274.

Figure 11. Magnetic resonance angiograms show the aorta of OPN null mice to be
the same size as wild type mice. Mice (Wild type: n=2, OPN null: n=2) were
anesthetized with avertin and examined in a magnetic resonance imaging scanner intended
for human use. As the diameter of the aorta varies along its length, only a single
measurement from a comparable location (indicated by arrow) was made from each
mouse. Despite the poor resolution, the aorta diameter of OPN null mice (n=2) can be
seen to be not significantly different than that of wild type (n=2).
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Figure 12. The loss of osteopontin results in the increased arterial wall
circumferential compliance of the common carotid artery. Left carotid arteries were

isolated from wild type and OPN null mice, then sutured to a catheter such that
intravascular pressure could be regulated. Intravascular pressure was slowly increased to
allow equalization. Diameters were then measured from digitized images taken at the
indicated pressures. (A) OPN null carotid arteries demonstrate greater compliance than
wild type at physiological pressures. Note that the increase in diameter of OPN null
vessels is greater than that of wild type. (B) Measurements of vessel diameter at the
corresponding pressure were used to determine vessel extensibility. The carotid arteries of
OPN null mice demonstrate greater extensibility than wild type at the pressures
determined in earlier experiments to be physiological for these mice. Asterisks (< 0.05).

Figure 13. The loss of osteopontin results in the increased arterial wall
circumferential compliance of the aorta. Segments of aortae extending from the renal

artery to the iliac bifurcation were isolated from wild type and OPN null mice, then
sutured such that intravascular pressure could be modulated 1 measured with standard
arterial line equipment. Arterial segments were then inflated with isotonic saline at 3
mumin. Digitized photographs were taken at indicated pressures. As the diameter of the
aorta differs along its length, only a single measurement from a comparable location was
made from each mouse. Arterial diameter was measured at sites indicated by arrows.
Indicated in each panel is vessel size as a percentage of the relaxed vessel and vessel size
as a percentage of the expanded vessel at 175 mm Hg. OPN null mice demonstrated
greater arterial wall compliance than wild type mice as indicated by a greater increase in
vessel diameter at both 80 mm Hg (wild type: 106% of relaxed diameter, OPN null: 153%
of relaxed diameter) and 175 mm Hg (wild type: 141% of relaxed diameter, OPN null:
164% of relaxed diameter). Bar = 2mm.
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Figure 14: The aortae of OPN null mice demonstrate increased compliance. Aortae
were isolated from wild type and OPN null mice, then sutured to a microinjector such
that intravascular pressure could be regulated. Diameters were then measured from
digitized images at indicated pressures. Regression formulae and associated R2 describe
data for both wild type (top) and OPN null mice (bottom)

Figure 15. The presence of osteopontin does not affect the longitudinal compliance
of the common carotid artery. Left common carotid arteries of equal length fiom a wild
type (n=l) and an OPN null mouse (n=l) were mounted in a petri dish so as to
photograph the vessels before and after application of a known force along the
longitudinal axis. No difference in vessel length was observed between wild type and
OPN null mice.

Figure 16. Collagen fibers are organized more loosely in vessels of OPN null
mice. Sections fiom unrnanipulated carotid arteries were stained with orcein (A, B) or
Massonis trichrome stain (C, D) to visualize elastin and collagen, respectively. No
difference in organization of elastin fibers was noted in wild type (A) versus OPN null
vessels (B). However, the organization of adventitial collagen fibers in arteries from OPN
null mice (D) appeared looser compared to wild type arteries (C). Elastin appears brown
in A and B, collagen appears blue in C and D. Bar=20
mum.
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Figure 17. Osteopontin expression is upregulasted following carotid artery
ligation. (A) Western blot of 100 mg of total protein from individual carotid arteries was
performedwith 12.5% SDS-PAGE followed by blotting with anti-OPN. (B) OPN bands
were then quantified following normalization against smooth muscle a-actin. The blot
was repeated in triplicate and results are reported as mean with standard deviation.

Expression of OPN following blood flow cessation in carotid arteries
To quantif) the temporal induction of OPN protein following carotid artery
ligation, vessels from OPN null or wild type mice were collected at 4 and 14 days after
ligation. Sham manipulated vessels were collected as control samples. Single ligated left
carotid arteries from each group were homogenized, then analyzed by Western blot for
the presence of OPN (Figure 17A,B). OPN protein in each vessel was quantified by
densitometric comparison and normalized to smooth muscle a-actin levels. Antibodies to
smooth muscle a-actin was used instead of antibodies to smooth muscle fl-actin in an
effort to normalize the length of the arterial segment analyzed (proliferation of cells

following ligation would be expected to increase the amount of p-actin present as
compared to an equivalent length segment of uninjured artery. We sought to determine the
differential expression of OPN in arterial segments of equivalent length, as opposed to the
number of cells present.) In vessels from wild type mice, low levels of OPN were
detected in unmanipulated carotid arteries. OPN protein was increased at 4 days after
ligation, and was abundant at 2 weeks after ligation. No OPN was detected in any arterial
samples from OPN null mice.

Vascular remodelinp response is replated by OPN
We used the carotid artery ligation model to test the hypothesis that OPN
regulates vascular remodeling responses. Groups of wild type and OPN null mice were
ligated with sham manipulation and unmanipulated mice as control. Carotid arteries were
then harvested at 14 and 28 days following ligation. We chose to harvest the carotid
arteries at 14 and 28 days following the procedure as previous work has indicated these
times to be optimal for proliferation92, and a time of stable neointima formation91
respectively. Eight sections from the proximal 2.25mm closest to the ligature were
analyzed from each mouse (Figure 18). No differences in vessel areas were found
between unmanipulated and sham manipulated arteries (Table 6). Consistent with their
increased compliance upon isolation from the body, the unmanipulated carotid arteries in
OPN null mice were significantly smaller than those in wild type counterparts (Table 6).
Following ligation, the ligated left carotid artery in all mice showed negative remodeling
(decrease in total area), while the contralateral right artery underwent positive remodeling
(increase in total area).
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The ligated left carotid artery of OPN null mice showed significantly less
neointima formation and greater constrictive remodeling (as evidenced by change in total
area) at 14 days following ligation compared to that of wild type mice (Table 6 ) .
Interestingly, the negative remodeling occurred such that the lumen area was no longer
different between groups. At 28 days following ligation, additional remodeling resulted in
similar intimal, lumen, and total areas between wild type and OPN null mice. At t h s time,
only medial area demonstrated a significant difference, and was smaller in the OPN null
than wild type vessels. Thus, the carotid arteries of OPN null mice displayed different
remodeling responses to arrive at 28 day remodeled arteries that were morphologically
similar to controls.
The right common carotid artery of all mice showed compensatory increases in
lumen area (p<0.001) and total area (p<0.001) with no significant changes in medial or
intimal areas as compared to unrnanipulated vessels (Table 7). Consistent with having
increased compliance, the actual change in lumen area was greater in OPN null mice.

Repression analvsis describes osteopontin effects on the response to carotid artery
lipation in preater detail
Having demonstrated the loss of OPN to alter the vascular injury response, we
sought to determine if OPN affected how the injury response changed with distance from
the site of ligation. Using the analytical method described in chapter 2, we found the
response of OPN null mice to be dramatically different than that of wild type mice.
Whereas wild type mice showed changes in vessel areas with increasing distance from the
site of ligation, OPN null mice did not. Additionally, the changes in vessel areas that
characterized the wild type response changed with harvest time. Though OPN null mice
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Medial Area
Control

1146

Intimal Area

1Control

28d

Wild Type
3PN Null

Lumen Area
Control

Total Area

14d

28d

Control

Wild Type 0.064 +/0.008

0.022 +/0.018

0.019 +/0.001

0.081 +/0.009

OPN Null 0.057 +/0.008
P(wt/null) 0.002

0.019 +/0.013
0.420

0.024 +/0.0 19
0.087

0.074 +/0.009
0.005

Table 6. Traditional morphometric analysis of the ligated left carotid artery.
Comparison of the injury response of OPN null mice to wild type mice was first done
with mean areas for the entire vessel as described by Kumar and Lindner9 1. Mean medial,
intimal, lumen, and total areas from left carotid arteries harvested 14 and 28 days
following left carotid artery ligation, and from left carotid arteries harvested from
unrnanipulated mice are presented. Data from sham manipulated mice did not differ from
unrnanipulated at any time point. Two way ANOVA (OPN/harvest time) indicated OPN
to have a significant effect that was then clarified with Studentis t tests. At 14 days
following ligation, OPN null mice demonstrated greater constrictive remodeling (as
indicated by a decrease in total area) and less neointima formation than wild type mice. At
28 days following ligation, with the exception of medial area, the remodeled arteries of
OPN null mice did not differ from wild type. Values presented are average areas (rnm2)
S.D. NA: values too small to be precisely measured. Italics indicate statistical significance.
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Table 8. Regression models describe how osteopontin is affecting the response to
carotid artery ligation. Though the response to ligation changed with harvest time in
both wild type and OPN null mice, the response of wild type mice showed vessel area
changes with distance that were not constant at each harvest time. Checked boxes indicate
the associated parameter was found to be statistically significant ( ~ ~ 0 . 0 5 ) .

Cell proliferation and apoptosis
Our morphometric analysis demonstrated that the loss of OPN does not affect
remodeling responses along the vessel in a uniform manner. We sought to determine if the
observed difference in neointima formation at 14 days between wild type and OPN null
mice could be explained by altered cell proliferation or apoptosis. Sections directly
adjacent to those analyzed for morphology were used to determine intimal cell number.
At 14 days following ligation, no difference was observed in the total number or
distribution of intimal cells (Figure 19A). Total cell number was observed to correlate
with intimal area. Sections were additionally analyzed for proliferation by
bromodeoxyuridine incorporation. Again, no difference was observed in total number of
proliferating cells (Figure 19B). As with total cell number, cell proliferation correlated
with intima area with approximately 10% of intimal cells undergoing proliferation.
Apoptotic cells were quantified on adjacent sections using a fluorescent deoxyribonucleic
acid end labeling assay (Figure 19C). In both wild type and OPN null mice, apoptosis
was observed in only 1% of the intimal cells. Like cell proliferation, the presence of
intimal apoptotic cells was observed to correlate with intimal area. While these particular
experiments do not indicate differences on the OPN null background, the results
demonstrate that the size of the neointima correlates with high rates of cell turnover.
Thus, the injury response at the cellular level also demonstrates regional differences.
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Rich inflammatorv infiltrate follow in^ carotid artery li~ation
As OPN has been shown to control the influx of inflammatory cells in vivo, we
examined if early inflammation was quantitatively different between OPN null and wild
type animals. Using an antibody against the pan-leukocyte marker CD45, immunostaining
was performed on sections of carotid arteries from both groups collected 4 days after
ligation. In sections from wild type animals, CD45 positive leukocytes were abundant in
the region with the largest neointima, but rare in the remainder of the vessel (Figure 20A).
Analysis of OPN null animals revealed few leukocytes in any region along the entire
length of the carotid artery (Figure 20B). Quantification of the area of positive
immunostaining of wild type mice showed a 10-fold increase over that of OPN null mice.
We attempted to specie the type and activation state of the invading inflammatory cells
using antibodies to CD-4, CD-8, CD-25, and CD-45 with flow cytometry. A digest time
could not be found that allowed cell dissociation, and cell viability.

.
wild type

OPN null

H

Figure 20. Leukocyte infiltration is diminished in OPN null mice. Representative
section from wild type (A) and OPN null (B) vessels harvested 4 days following ligation
in regions close to the ligature are shown. Sections were stained with anti-CD45 panleukocyte antibody. Note the absence of leukocytes in the OPN null sections. Arrow in
panel B shows a region of some leukocyte influx. Bar = 500 pm.

Chapter 3 Discussion
Both gene products and physical forces have been shown to affect vascular
physiology / pathophysiology. In this study, the loss of OPN was shown to alter
hemodynamics and arterial mechanics. As normal wild type mice express very little OPN
in blood vessels, our findings of significant changes in normal blood vessel physiology on
the OPN null background was unanticipated. Compared to wild type, we observed
manipulated OPN null mice to have more lymphocytes, lower systolic blood pressure,
increased heart rate, arteries with greater compliance, and reduced blood flow at similar
heart rates. These observations are consistent with previous work which has observed
increased systolic pressure associated with stiffened vessels22-24. Though increased
compliance can increase the lumen area of resistance vessels thus reducing peripheral
resistance / blood pressure, other factors must be considered as tlus has not been observed
in every case31750,70. However, contrary to the predictions of carnpbel121 (Cardiac
output = mean arterial pressure x (compliance / time constant)), we observe increased
compliance in the presence of decreased cardiac output, suggesting the lowered systolic
pressure observed in the OPN null mice of this study may reflect lowered mean arterial
pressure. Interestingly, the difference in large artery diameters predicted by our
compliance data was not observed in an in situ comparison of OPN null mice to wild
type. Though our in situ observations were not in alert mice (and we did not measure the
blood pressure of the anesthetized mice), we interpret this inconsistency as supportive
evidence of a compensatory increase in vascular tone in OPN null mice.
Our data support the following model of OPN activity in the normal vessel wall
(Figure 21). As OPN null mice are similar to wild type in size, physical activity, and
oxygen carrying capacity (Table 5, and data not shown), blood flow is similar in both
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groups. Because of the lack of OPN, vessel wall compliance is greater, resulting in
decreased systolic pressure. Though the OPN null mice attempt to compensate for
increased compliance with increased smooth muscle cell tone, this compensation is
incomplete as evidenced by lower blood pressure [Arterial pressure=(flow)(vascular
resistance)]. Additionally, the loss of OPN is associated with reduced stroke volume
which is compensated for by an increased heart rate ~low(stroke volume)(heart rate)].
Although the OPN null mice are overtly similar to wild type mice, our model predicts the
mice to be compromised upon cardiovascular challenge.
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Figure 21. Model of altered hemodynamics in OPN null mice. The structural

changes noted on the OPN null background include disorganized collagen and increased
vessel wall compliance. OPN null mice compensate for increased vascular compliance
with increased vascular tone, and reduced stroke volume with increased heart rate.

The structural change involving the collagen matrix is of interest, as OPN is
thought to interact with collagens186,201, fibronectin202, and other components of
specialized matrices including osteocalcinl74. With respect to collagen, we previously
found that on the OPN null background, wound healing in the skin occurred with a defect
in the fibrillar organization of collagen, and formation of large dermal collagen fibrils was
lachg281. Similarly, following myocardial infarction, Trueblood et al. observed increased
dilation in the presence of smaller and more loosely organized collagen fibers in the
remodeled heart of OPN null mice as compared to wild type283. In arteries, the
circumferential stretch of arteries has been shown to mostly involve elastin and collagen
structure13,18,284.Functionally, defective collagen organization has been shown to
increase aortic compliance and reduce strength19, which is consistent with our
observations. Collectively, these observations suggest that the presence of OPN is
important for matrix remodeling and collagen structure in vivo, and suggests that OPN
modification of collagen structure may be the molecular mechanism underlying the altered
compliance of OPN null mice.
As we had hypothesized, we found that the remodeling response of OPN null
vessels to cessation of blood flow was distinct from that in wild type vessels. The
response to carotid artery ligation has been shown to be mediated by factors affecting
18, plasma proteins84,92,100,1 14, cytoskeletal
inflammation101,vascular t0ne2~~10271
components32, hormones 1 growth fa~tors13~,135.
Following ligation, OPN null mice
demonstrated greater initial constrictive remodeling and less neointima formation as
compared to wild type. The observation of decreased neointima formation in the response
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of OPN null mice to carotid artery ligation is consistent with our previous observation of
decreased neointima formation following endothelial denudation in rats treated with antiOPN antibody280. As it was possible that the increased constrictive remodeling reflected
an endothelium dependent response, we re-examined our earlier data using anti-OPN
Similarly, we found
antibody infusion following balloon catheter den~dation2~0.
significantly increased constrictive remodeling in the anti-OPN treated group compared to
wild type (Figure 22). This suggests that blocking OPN function may be a means to
increase vascular compliance. Another consistent finding between the endothelial
denudation model and the carotid artery ligation model was that we could not detect
changes in cell proliferation, apoptosis, or cell density.

"'I T

Figure 22. Following endothelial denudation, rats demonstrate less constrictive
remodeling in response to anti-OPN treatment. Previously published data concerning
the effect of OPN on the vascular remodeling of rats following endothelial denudation was
reexamined. Consistent with the data presented in this chapter, the loss of OPN resulted
in decreased constrictive remodeling. Single asterisk indicates a previously described
significant difference. Double asterisks indicate significant difference found on review.
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OPN null mice, despite having more circulating lymphocytes, did not demonstrate
the early leukocyte infiltration that characterized the response of wild type mice. OPN
has been verified as an important mediator of immune cell migration and activity285 and
leukocyte invasion has been observed to be an important determinant of neointima
formation. For example, decreased leukocyte infiltration was associated with reduced
neointimal size in P-selectin null mice109 and endothelial nitric oxide synthase transgenic
rnicel02. Conversely, endothelial nitric oxide synthase deficient mice demonstrated
greater neointima formation in the presence of increased leukocyte infiltration27 and fas
ligand deficient mice showed increased neointima formation preceded by increased
leukocyte infiltrationl68. While our study supports a positive association of leukocyte
infiltration and neointimal lesion size, we also observed increased constrictive remodeling
associated with decreased neointimal lesion size in OPN null mice. Interestingly, this
altered remodeling occurred in such as a way to maintain the remodeled lumen size. The
mechanism of the altered response will require additional study. Whle we hypothesized
that loss of the macrophage chemoattractant properties of OPN would directly alter the
vascular injury response of OPN null mice, the altered response may be secondary to the
unexpected difference in hemodynamics/vessel mechanics. This alternative explanation is
supported by several studies that have observed an association of inflammation with
increased blood pressure242,286.
As hypertension has been observed with increased ~alcification2~3,287,
and Speer
et al.278 observed increased induced arterial calcification in mice on an OPN null 1 Gla null
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background, our observation of decreased blood pressure and increased compliance in
OPN null mice initially seemed counterintuitive. It is most likely that the altered
hemodynamics I vascular mechanics of OPN null mice are due to both primary and
secondary effects of loss of OPN. We suspect the loss of direct inhibition of calcification
by OPN overcomes the secondary feature of lower blood pressure. Thus, our
observations rather than conflicting with those of Speer et al. combine to demonstrate the
many factors that must be considered when analyzing vascular response.
In summary, the regulation of vascular function is indeed complex. This study
demonstrated OPN to have a role in determining the hemodynamics I vessel mechanics of
normal arteries as well as remodeled vascular phenotypes. Our data, combined with that
of others, suggests alteration of collagen structure may be the mechanism by which
compliance is changed in OPN null mice. We are currently seeking to distinguish which of
the observed effects are primary and secondary due to loss of OPN.

Chapter 4
SUMMARY, FUTURE PLANS, AND RESEARCH DESIGN

Summarv
The work presented in this text makes a significant contribution not just to the
study of chronic obstructive vascular disease, but to the general study of vascular biology
as it identifies OPN as not only having a role in vascular injury response, but in the
function of normal, healthy arteries as well. Comparison of the morphology of the
carotid arteries of wild type mice to OPN null mice before and after vascular injury
demonstrated that OPN does not affect the morphology of large arteries before vascular
injury or after stable lesion formation, but does affect the path by which the stable lesion
is acheved. Comparison of the vascular function of large arteries between wild type and
OPN null mice demonstrated the hemodynamics of uninjured OPN null mice are different
than wild type mice, and the physical / structural characteristics of the large arteries are
different as well. Comparison of the complete count of OPN null mice to that of wild
type mice revealed OPN null mice to have a greater concentration of lymphocytes. The
loss of OPN was shown to result in decreased inflammation and followed by less
neointima formation. Additionally, the work demonstrated the first application of
regression to the analysis of carotid artery ligation data that, due to increased comparative
power and quality of description, should facilitate future experimentation and
interpretation of studies. The work was exciting to perform as the differences between
uninjured wild type and OPN null were not expected.
The work presented in this text has several limitations that prevent further
interpretation of the results as they relate to the projectis goal, the determination of the
mechanism by which OPN affects the vascular injury response. The major problem is the
presence of OPN caused differences in the negative controls for the vascular response
(sham manipulated and unmanipulated mice). Though this observation is exciting as it

demonstrates the first vascular phenotype of uninjured OPN null mice, and suggests that
OPN may be a novel target for blood pressure therapy, the lack of equivalent baseline
complicates analysis. The difference observed in the vascular injury response of OPN null
mice from that of wild type mice may be due to conditions that existed prior to injury.
This limitation occurred because we simply did not expect the small amount of OPN
present in the vessel prior to injury to have a significant effect on vascular function. In
retrospect, in vivo systems are complex, and the action of OPN at sites other than the
vasculature must be considered as it may have secondary effects on the vasculature. For
example, it is possible that the expression and action of OPN in regions of kidney
involved with blood pressure regulation affected hemodynamics such that the structure of
the vasculature compensated with altered compliance. Additionally, as inflammation has
been shown to correlate with blood pressure242, the diminished inflammatory response
of OPN null mice may be secondary to reduced blood pressure. We chose to complete the
study with the belief that the full data would help us design better follow-up experiments,
and any follow-up experimental design would require the data.
A second limitation of the data that prevents further interpretation is the complete
lack of data on vascular function after injury. Thus, the effect of vascular injury on
hemodynamics and vascular compliance is not known. As expression of OPN increased
following injury and a difference in injury response was observed at this time, the
simultaneous observation of an effect of OPN on either compliance or hemodynamics
would have greatly helped this study. This limitation occurred because of time
constraints: the need to return borrowed equipment and a shortage of mice. Fortunately,
these problems can be addressed in follow-up experiments.

A third limitation of the data is the failure to localize OPN expression. This
occurred due to technical problems with OPN immunostaining. Despite attempts with
several different antibodies, the technical problem (localization of non-specific antibody
to the same area) could not be overcome. Thus, though OPN expression was quantified
before and after injury with western blot, the location of the expression is not known. In
the laboratory, we are currently developing rabbit polyclonal anti-mouse antibodies that
may help us address this problem. The presentation of altered adventitial collagen in the
uninjured vessels of OPN null mice as compared to wild type suggests OPN is directly
involved in organization of these collagen fibers. However, previous work in rats did not
demonstrate the adventitia to be a site of OPN expression in uninjured vessels. It is
possible the altered collagen appearance results from compliance effects on the movement
of the vessel wall with each pulse wave. Possible solutions to this problem include the
use of frozen sections instead of paraffin embedded sections, or the use of in-situ
hybridization.
Despite these limitations, the data presented in this text does allow the projectis
hypothesis to be addressed. We accept the hypothesis. The data presented in this
text clearly shows that the presence of osteopontin does affect the response to
vascular injury. However, the failure of the hypothesis to consider the expression of

OPN prior to injury as a source of alteration of the injury response reveals the flawed
reasoning in hypothesisi conception, and prevents achievement of the project goal (i.e.
determination of the mechanism of action of OPN in vascular injury). As presented in the
following sections, the continued advancement of this project centers on the formulation
of a hypothesis that considers what was learned in the execution of this portion of the
project.

Future plans
Though capable of addressing the projectis hypothesis, the data presented in this
text does not adequately address the projectis goal, which was the determination of the
mechanism by which OPN affects the vascular injury response. Given that OPN affects
the h c t i o n of uninjured blood vessels, the future goal requires an examination of the role
of OPN in the function of uninjured vessels. Thus, though the overall goal remains the
same, the future goal must be more specific. The revised project goal is to

mechanistically describe the role of osteopontin in normal vascular function. The
successful attainment of this goal will improve our understanding of the basic processes
that underlie vascular h c t i o n . As the data presented in this text identified OPN as a
mediator of vascular compliance, the targeting of OPN may be therapeutically useful. As
there are currently no drugs that directly alter vascular structure, if OPN proves to have
direct action on the vasculature, then pharmacologic agents that act on OPN would
represent a novel drug class. The revised project goal will be addressed with the

proposed hypothesis that osteopontin alters vascular function through a direct
effect on collagen. The projectis hypothesis could be tested with the following strategy.
Project strategy: Identify the effect of osteopontin on factors known to be involved
with vascular function. To advance the project, two specific aims are proposed. Their
successful achievement should allow the proposed hypothesis to be addressed, and
provide substantial data toward the achievement of the revised project goal .

Specific Aim 1: Identifjl the structural basis for the difference in compliance between
wild type and OPN null mice.

Specific Aim 2: Identifjl the basis for the difference in vascular tone between wild type
and OPN null mice.

Research d e s i ~ n
Specific Aim 1: Identify the structural basis for the difference in compliance between
wild type and OPN null mice
Hypothesis: Osteopontin binding of collagen alters collagen fiber formation and
organization.
Strategy: Comparison of electron micrographs of the vessel wall of OPN null mice to
that of wild type mice in conjunction with osteopontin-collagen 1 elastin binding assays.

Is the altered compliance of OPN null mice accompanied bv altered elastin1
colla~enstructure?
Regardless of whether the effect of OPN on the vasculature is primary or
secondary to OPN action elsewhere, the arterial wall of OPN null mice is physically
different than the equivalent arterial wall of wild type mice. This difference is not due to
vascular tone as the pressure myograph experiment in chapter 3 was conducted in the
presence of high concentration of vasodilator. Besides vascular tone, compliance is
primarily mediated by collagen and elastinl3. The lack of difference in the longitudinal
extensibility of the carotid artery between groups suggests the difference in
circumferential compliance to be due to altered collagen18. Additionally, adventitial
collagen appeared less dense in OPN null mice as compared to wild type (Figure 16).
Alterations of collagen with the loss of OPN is further supported by previous work as
our laboratory281 and others283 have noted OPN null mice to have thicker collagen fibers
in a less dense matrix than that of wild type mice.

As compliance is affected by the geometric arrangement of the collagen fibers as
well as both the type and amounts of collagen expressed, analysis will include both
quantification and examination of the collagen network. The carotid artery will be used as
the composition of the aorta has been shown to vary along its length20. Carotid arteries
will be harvested from groups of 16 week old wild type and OPN null mice (n=6 from
each group), normalized for total protein, and then quantified for total collagen and elastin
by western blot. Though collagen is normally insoluble, the quantification of total collagen
by western blot has been described288 The quantification of collagen sub-type will be
done by immunostaining. As collagen fibrillogenesis is known to be mediated by many
factors and fibrils may form so as to mask the presence of a collagen sub-type, a brief
pepsin digest will precede irnmunostaining. Our laboratory currently has serial crosssections from carotid arteries of wild type and OPN null mice. These sections (n=6 from
each group) will be immunostained with fluorescent tagged antiboles to collagens I, 111,
and V (Southern Biotech), and digitally photographed. Total light can then be used to
quantify collagen sub-type in each vessel layer. Non-specific fluorescent labeled IgG will
be used to assess non-specific binding. As it was successfully used in previous analyses
of the OPN effect on collagen networks281,283, examination of the collagen network will

be done with a comparison of electron micrographs of cross sections of the carotid artery
(n=6 from each group). The subjective work will be summarized with the selection of a
representative section from each group.
The expected result of these experiments is to confirm the collagen structure of the
arteries of OPN null mice to consist of thnner fibers in a less dense matrix than wild
type. The work presented in the text (Figure 16) suggests elastin structure is not altered

in OPN null mice. Consistent with this result, there are no reports of OPN binding
elastin. However, Giachelli et al. used immunostaining to localize OPN near the elastic
laminae274. Thus, it would not be especially surprising to find the ultrastructure of
elastin to be altered by the loss of OPN.
A problem with the electron microscope experiments is the lack of quantitation.
The difference in elastin1 collagen structure between groups would have to be obvious for
the experiments to be at all convincing. Though this is the expected result for collagen, if
the result is not obvious, then the quantification of density of collagen matrices will be
attempted using a variation of a procedure described by Ramanujan et a 1 . 2 Briefly,
~~
fluourescein labeled dextrans of variable molecular weight (Sigma) will be allowed to
permeate the freshly harvested vessels of wild type and OPN null mice. The tissue
permeation should not be a problem as Netti et al. were able to monitor the flow of large
molecules through tumor tissue290. Assuming success, the vessels successfully
permeated with the heaviest dextran will then have a small (20 pm radius) spot exposed
to 488 nrn laser light so as to permanently bleach the exposed fluorochromes. The
increase in light over time can then be measured as unbleached fluorochromes diffuse into
the area to provide a measure of barrier to diffusion. Whereas the barrier to diffusion of
small molecules is primarily effected by proteoglycans, the movement of large molecules
is primarily effected by the collagen matrix290. Comparison of the diffusion times for
large molecules should then provide a quantitative measure of density of the collagen
network.

Does osteo~ontincolocalize with collagen or elastin?
Both ~ u t l e r l 8 6and Kaartinen et a1.201 demonstrated OPN binding wells coated
with collagens I-V. Butler reported dissociation constants ranging from 20-50 nM, and
Kaartinen showed collagen type V binding to be stronger than type I and type I binding
stronger than type 111. However the in vivo binding of OPN to collagen has not been
shown. Assuming the technical difficulties with irnrnunostaining can be resolved, the OPN
antibody will be tagged with a fluorochrome (Fluoreporter labeling kit, Molecular Probes),
and used to demonstrate colocalization in confocal micrographs with the fluorescent
tagged collagen antibodies (Southern Biotech) and with elastin antibodies (Elastin
Products Company). With proper selection of fluorochromes, the excitiation of one
fluorochrome by the light emitted from the other fluorochrome can be used to localize the
antibodies to be close ( 10-100 angstroms) to each other. However, as background
fluoresence levels need to be especially low for FRET to be valid, and staining
ofextracellular matrix typically shows at least some background staining, a false positive
result may occur. Thus, as always, good controls are necessary. The demonstration of
fluoresence resonance energy transfer will clarify the colocalization as it will rule out all
but very small bridge molecules. Even if fluoresence resonance energy transfer is not
possible in this system, the experiment will verify or rule out colocalization.
The expected result of this experiment is the demonstration of colocalization with
fluoresence resonance energy transfer of OPN with collagen in the medial layer. The
binding of osteopontin to collagen has been described and the presence of both has been
described in the medial layer. Though the work in this text showed collagen structure to
be altered in the adventitial layer of OPN null mice, Giachelli et al. showed osteopontin
not to be expressed in this layer274. The colocalization of osteopontin with elastin is also
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expected as Giachelli et al. have already made t h s observation274, but the observation of
fluoresence resonance energy transfer with the elastin colocalization would be especially
interesting as the binding of osteopontin to elastin has not been reported. The requirement
for a bridge protein for the binding of OPN to elastin/ collagen will be tested using in vitro
experiments whch will be described.

3
corn ~liance?
In chapter 3 a model of the action of OPN proposed OPN null mice to have
greater vascular tone in compensation for their increased compliance. As chapter 1
describes that vascular compliance can be altered by hemodynamics, it is equally possible
the increased compliance of OPN null mice occurs in compensation for increased vascular
tone. To determine whether the action of OPN on the vasculature is direct or secondary
to its action at another site, the compliance of vessels with an increased concentration of
OPN will be measured. As osteopontin transgenic mice are available, the effect of
increased OPN expression on compliance can be determined by comparison of pressure
myograph measurements of compliance of these mice to those presented in chapter 3.
In addition, the effect of the increased expression of OPN following ligation will
be determined by comparison of pressure myograph measures of compliance of the 4, 14,
and 28 day ligated vessels of wild type mice to those of OPN null mice. As it is unlikely
the local increase in OPN will affect any other sites in the body, a further decrease in
circumferential compliance in response to increased vascular OPN would suggest a direct
effect. As demonstrated in chapter 3, ligation of the left common carotid artery results in
increased expression of OPN in the region around the ligature. Groups of wild type mice
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(n=6) will have left common carotid arteries ligated, then harvested at 4 days, 2 weeks, 4
weeks, and 8 weeks. Compliance of the vessels will be determined using the pressure
myograph technique also described in chapter 3. As they can also affect compliance,
following measurement, collagen and elastin will be quantified by western blot and
irnrnunostain as described above.
Though not conclusive, these are especially exciting experiments as they will
provide evidence as to the vessel being a primary site of osteopontin action. The data
presented in this text showed less constrictive remodeling in wild type mice at a time of
increased OPN expression. The linther decrease of compliance in response to additional
OPN could explain this result. Certainly there are other molecular changes induced by
ligation (chapter one), but few follow the kinetics of OPN. Tracking changes in
compliance with the change in OPN over time will either refute or further support a role
for OPN in mediating compliance. The drawback of the experiment is it can not control
for other differentially expressed proteins that follow OPN kinetics. Thus, the observed
effect, if there is one, may be due to the action of a protein other than OPN, so the
expected result of this experiment is evidence that further supports OPN mediation of the
compliance of the carotid artery.

Does osteopontin have multiple collayen or elastin bind in^ sites?
Though the use of recombinant OPN in the binding assays of Kaartinen et al.
demonstrated post-translational modification of OPN is not necessary for collagen
binding201, previous binding assays did not identifjl the specific collagen binding site(s)
on OPN. The binding domains required for OPN binding of collagen will be determined by
measuring the ability of increasingly smaller fragments of OPN to bind collagen.

Interestingly Kaartinen et al. found the binding of collagen by OPN to be calcium
dependent20l , suggesting the need to retain the calcium binding sites of OPN (aa 86-95
and aa 216-228) for collagen binding. Our laboratory currently has recombinant expressed
proteins equating to full-length OPN and fragments resulting from the matrix
metalloproteinase cleavage of OPN (OPN40kD: aa 17-166,OPN32kD: aa 167-314,
OPN25kD: aa 2 11-314, OPNI 5kD: aa 167-210). These fragments can be used to further
localize the binding site(s). The OPN fragments1domains will be quantified, radiolabeled
(Custom label service, Amersham Bioscience) then serially diluted. The solutions will
then be placed in wells coated with known amounts of collagens I-V. Wells coated with
bovine serum albumin will be used as negative control201. The free OPN will then be
washed from the wells, and bound OPN will be quantified using the radiation emitted
from each well. Though the Scatchard plot has been used for determination of binding
strength and valence, it has been criticized both in theory291 and the way it has been
applied292. A simpler and more accurate analysis has been described by Lodish et a1.293
From the data, a plot of bound OPN vs. OPN dilution will be made. Non-specific binding
will be determined by carrying out the same experiment in the presence of 100 fold excess
unlabeled OPN. As the specific binding sites will be occupied by excess OPN, labeled
OPN will represent non-specific binding at each concentration. The specific binding at
each concentration can then be determined by subtraction of non-specific binding from the
total binding determined by the first experiment. The valence can be determined by the
number of bumps in the curve, or, as it is possible different sites may have the same
affinity, from the amount of OPN required to saturate a known amount of collagen 1
elastin. As the binding constant KD is defined as the concentration of ligand necessary to
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bind half the receptors, inspection of the graph will provide a close approximation. The
application of curvilinear regression to the data can locate KD with greater precision. Our
recombinant protein expression system will then be used to express smaller OPN
fragments to further refine the required protein region(s).
Elastin will also be assayed for its ability to bind OPN. Should such binding occur,
the OPN binding sites for elastin will be similarly determined. The identification of
multiple collagen or elastin binding sites would indxate OPN ability to form aggregates.

Can osteopontin alter the comoliance of elastin1 colla~enmatrices in vitro?
In vitro work will also include analysis of the effect of OPN binding on the
physical properties of elastin and collagen matrices. The formation of

and

elastin295 matrix disks have been described. Separate disks containing collagen I-V and
elastin will be made with increasing amounts of OPN (the upper limit to be lox the
concentration of OPN in injured vessels ). Bovine serum albumin will be substituted for
OPN as a negative control. The deformation of the disks in response to the application of
force will then be quantified from digital photographs to provide measures of compliance.

Additional experiments will be done with OPN fragments1 domains as indicated by the
binding assays.
The drawback of this experiment is its inability to accurately represent the
geometry of the matrix in vivo. Collagen fibrillogenesis is known to be mediated by many
factors (e.g. temperature), and the complexity of in vivo regulation of collagen
fibrillogenesis simply can not be replicated in vitro. However, the study of the effects of
OPN fragments in this system could provide the mechanism by which OPN mediates
compliance as well as the specific domains necessary. The expected result of this
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experiment is the disks containing OPN (or the collagen binding domains) and collagen
will demonstrate decreased compliance through a mechanism that involves OPN bridging.

Specific Aim 2: Identify the basis for the difference in vascular tone between wild type

and OPN null mice.
Hypothesis: The presence of osteopontin decreases the reactivity of smooth muscle

cells to vasoconstricting hormones.
Strategy: Comparison of amounts of factors known to affect vascular tone between wild

type and OPN null mice in conjunction with reactivity assays.

% D

Our model of the action of OPN in blood vessels has smooth muscle cells showing
increased tone in the absence of OPN. The evidence supporting this aspect of the model
is weak as we compared the in situ diameter of arteries of anesthetized mice to diameters
predicted by arteries in vitro treated with vasodilator. A better comparison can be made
with measurements of the exposed carotid arteries of anesthetized mice simultaneously
monitored for blood pressure, blood flow and heart rate. The response of the arteries to
vasodilators and vasoconstrictors can then be determined. It is possible that the
manipulation of heart rate and blood pressure of anesthetized mice with epinephrine and
intravenous fluids may allow the hemodynamics of alert mice to be replicated.
Interestingly, atropine has little, if any, effect on mice due to their poorly developed
parasympathetic nervous system,
Smooth muscle cell reactivity will be quantified with functional assays. Smooth
muscle cells from OPN null mice will be grown on elastin and collagen matrix disks

described earlier in both the presence and absence of OPN. Similar to the previous
experiments, the deformation of the disks in response to being released from the dish will
then be quantified. The experiment will be repeated in the presence / absence of known
vasoconstrictors / vasodilators. The resulting data will address the reactivity of smooth
muscle cells to vasodilators 1 vasoconstrictors in the presence / absence of OPN.
It is expected that these experiments will identifl a quantitative difference in
either vasodilators/ vasoconstrictors, their associated receptors, or smooth muscle cell
reactivity. To confirm the result in vivo, carotid arteries will be harvested from wild type
(n=6) and OPN null mice (n=6), mounted in a pressure myograph. The vessels will then
be inflated to 140 mm Hg, and digitally photographed before and after treatment with
vasodilators/ vasoconstrictors identified in earlier experiments to be differentially
involved. The response can be measured against the pressure dlarneter curves shown in
chapter 3.
Though OPN is a substrate for smooth muscle cell attachment285, it may be that
OPN affects smooth muscle cell binding to collagen or elastin through competition for
binding sites. If this were true, OPN null mice show greater vascular tone simply because
they grip the extracellular matrix better. While this may appear unlikely, our laboratory
has observed the presence of OPN and specific fragments of OPN to substantially affect
cell adhesion (unpublished results). To rule out OPN effects on smooth muscle cell
adhesion, the collagen and elastin disks in the presence of OPN and fragments of OPN
will be plated with a known number of cells. The cells will be allowed to set on the disk
for ten minutes, then unattached cells will be washed off Comparison of the number of
attached cells will demonstrate the effect of OPN on cell binding to extracellular matrix.

Limitations of the research d e s i ~ n
The proposed research design thoroughly examines the interaction of OPN with
collagen and elastin. Additionally, the experiments will identi@ the domains of OPN
necessary for interaction with collagen and possibly with elastin. As OPN contains no
known domains for these interactions, the domains identified will be novel and may
contribute to our understanding of other proteins. Furthermore, the proposed experiments
will identi@ the role of OPN in mediating vascular tone. Together these experiments will
allow the hypothesis that OPN affects vascular function through a direct interaction with
collagen to be addressed, and will provide critical information for the project goal of a
mechanistic description of OPN function in normal vessels. As described above, if OPN
does indeed have primary effects on the vasculature, these experiments could identi@ it
as a target for a new class of drugs. For these reasons, the proposed experiments, though
relatively simple, may be quite rewarding. However, the proposed design has two major
limitations:1) If OPN does not have direct action on the vasculature, then the proposed
experiments do very little to identi@ the primary site of action. Should the proposed
experiments show that OPN does not directly act on blood vessels, the differences in
smooth muscle cell reactivity and vasoconstrictor/ vasodilator1 receptor levels in OPN
null mice from that of wild type mice may provide insights to some candidate sites of
OPN action. 2) The experiments will not address the original project goal of this text,
determination of the role of osteopontin in vascular injury. Addressing the role of
osteopontin in vascular injury using the original strategy will require OPN null mice that
have been somehow normalized to wild type vascular function. The data that will result
from these proposed experiments should provide insights into how such normalization
could be done.

In general, the proposed experiments are relatively simple. As demonstrated by
the work presented in this text, many of the procedures have already been practiced.
Other potentially challenging tasks, such as recombinant protein expression, have been
worked out by others in the laboratory. The greatest technical problem in carrying out the
experiments is the lack of a key piece of equipment. The proposed research design relies
heavily upon electron microscopy to demonstrate structural differences between wild
type and OPN null mice. Unfortunately our laboratory possesses neither an electron
microscope nor the sample preparation materials. Thus, this aspect of the project will be
addressed through collaboration. One possible collaborator is the electron microscopy
facility at the University of Maine.

Timeline for the proposed research desiyn
The anticipated time to complete the proposed experiments is two years. A rough
estimate of the sequence and time commitment to the different parts of the project are
shown in Figure 23.

Time (months)

I
Recombinant protein synthesis
I
Domain binding assays
Compliance of ligated arteries
Electron microscopy of samples
B l d work

I
Receptor quantification
Fragment binding assays
Compliance of elastin1 collagen matrices
I
Co-local ization confocal microscopy
Smooth muscle cell binding assay

Figure 23. Anticipated sequence and time requirements for the different phases of
the proposed project.
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